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ABSTRACT 
Schatz, Robert Alfred. Ph. D., University of Rhode Island, June, 1972. 
Pargyline, Succinic Acid and L-Ascorbic Acid as Protective Agents Against 
Hyperbaric Oxygen Toxicity: Possible Involvement of Altered Gamma-
Aminobutyric Acid and Ammonia Metabolism . 
The mechanisms whereby pargyline, succinic acid and ascorbic acid 
protect againot hyperbaric oxygen convulsions, pulmonary damage and 
mortality follo~ing hyperbaric oxygen exposure were investigated in re-
l ation to the effects of these agents on hyperbaric oxygen- induced 
alterations in brain gamma-aminobutyric acid and ammonia metabolism . 
Exposure to hyperbaric oxygen (60 pounds per square inch, gauge 
pressure) produced convulsions, post-exposure lethality and elevation in 
lung weight, lung water content and lung hemoglobin content . Pargyline, 
succinic acid and ascorbic acid provided part:i.?.l protection against al l 
of the above aspects of oxygen toxicity. 
Comparison of the doses of pargyline , s~cc inic acid and ascorhic 
acid that provid8d maximal protect i on against hyperbaric oxygen convul-
sions shewed that aJ. l three agents were approximately equal , in the 
doses used, with respect to their effectiveness in decreasing the inci-
dence of hyperbaric oxygen convulsions and increas ing the latency to 
their onset. Pargyli>le and succinic acid \·?ere approximately equal, in 
th e doses used, in their ability to reduce post-exposure lethality and 
hyperbaric oxygen-induced increases in lung weight , water content and 
hemoglobin content. Ascorbic acid was less effective in its ability to 
reduce the above changes induced by hyperbaric oxygen exposure. 
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Hyperbaric oxygen decreased brain gamma-aminobutyric acid levels. 
This decrease was due to inhibition of glutamic acid decarboxylase without 
any effect on gamma-aminobutyric acid transaminase activity . Both 
pargyline and succinic acid increased brain gamma-aminobutyric acid levels 
in room air-exposed mice and prevented the decrease in brain gamma-
aminobutyric acid produced by hyperbaric oxygen exposure. Pargyline 
increased gamma-aminobutyric acid levels by inhibiting gamma-2~1inobutyric 
acid transar:iinasc activity in room air- and hyperb2ric oxygen-exposed 
n:ice. S1Jccinic acid increased the activity of both glutamic acid decar-
boxylase and ganma-ao inob utyric acid transaminase, glutamic acid decar-
boxylase to a greater degree than gaIILma-arninobutyric acid transaminase. 
Glut amic acid decarboxylase activity was still slightly increased in 
mice exposed to hyperbaric oxygen . These alterations in enzyme activity 
\7ere responsible for the ability of pargyline and succinic acid to 
increase brain ganuna- aminobutyric acid l evels in room air-exposed mice 
and to prevent the hyperbaric oxygen-induced decrease in brain gamma-
aminobutyric acid in animals exposed to hyperbaric oxygen. There was a 
significant correlation between hyperbaric oxygen seizure susceptibility 
and brain garr~1a-arai.nobutyric acid levels in pargyline- or succinic acid-
treate<l mice . 
In pargyline- or succinic acid-treated mice there was a dose-
response relationship between amount of c.lrug administered and degree of 
elevation in brain garnma-aminobutyric acid . 
Ascorbic acid had no effect on brain gamma-aminobutyrjc acid levels 
nor did it prevent the hyperbaric oxygen-induced decrease in brain garnma-
am inobutyric acid. Ascorbic acid tr eatment had no effect on glutamic acid 
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decarboxylase or gamma-aminobutyric acid transaminase activities nor 
did it prevent the hype rbaric oxygen-induced decrease in glutamic acid 
decarboxylase activity. 
Hyperbaric oxygen exposure increased brain ammonia levels and 
decreased brain glutamine levels. All three agents reduced these 
typerbaric oxygen-induced alterations . There was a correlation be-
t ween brain ammonia leve ls and hyperbaric oxygen seizure susceptibility 
in nice treat~d with pargyline , succinic ac id or ascorbic acid. The 
same was true f or glutamine leve ls and hyperbaric: oxygen seizure sus-
ceptibility . 
These n~sults demonstrate tha t decreased gamma-aminobutyric acid 
l evels and increased am.mania leve ls in the brain are involved in the 
etiology of hyperbar ic oxygen toxicity . The effect iveness of the 
three agents tested as protective agents again~ t hyperbaric oxygen 
toxic ity appears related to their ability to alter the hyperbaric 
oxygen- induced chanses in brain nmmonia and gamrna-aminobutyric acid 
metabolism. 
The relationship between hyperbar ic oxygen- induced alte rations in 
gamma-aminobutyric acid and ammonia metabolism and the effects of par-
gyline, succinic acid and ascorbic acid thereon are discussed with 
respect to mitochondrial function and consequent ad enos ine triphosphate 
production. 
To: A j h 
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I. INTRODUCTION 
With man's increasing quest for knowledge and search for natural 
resources other than those found on land, it is becoming more and more 
likely that man will encounter greater than norma l partial press ures of 
oxyg en i n various situations such as diving operations , space travel and 
us e of hyperbarlc oxygen in medicine. 
In the field of medicine , OHP is being emp loyed in t11e treatmen t 
of myocardial infar~tion (Peter ~ .§..!_., 1966) and shock (DelGuercio ~ 
~l·, 1966). Us~ of OHP to extend the s a fe-period cf circulatory arres t 
during sur gery (He i jne, 1966; Moo1: ~ .§..!_., 1966), psrt icularly of congen-
i ta l cardiac defects ( Ber~hard ~al., 1966), has been considered a life-
s aving procedure . OHP has also been use d in the treatment of anaerobic 
infecticns (Hitchcock e t_ al., 196 7; Jones, 196 7; Brummelkamp , 1966), in 
burn therapy (Taber, .196 7; Nelson ~ al. , 1966), in cancer chemo therapy 
(Church~ll-Davidson , 1966; Nathanson et al., 1966) and in treatment of 
carbon monoxide and cyanide poisoning (Norman ~ .§..!_. , 1970; Shene et al_., 
1966). 
For these reasons , man has become increa singly aware of the po3si-
ble value of OHP in many aspects of modern life . Man h as, however, also 
become aware of the toxic effects of OHP , which include muscle fascicu-
lations, convulsions, pulmonary damage and pos t--expos ure lethality. 
In recent year s , investigators have begun to explore the mechan-
ism(s) of this tox ic syndrome by using , as tools, drugs that ameliorate 
one or more of the aspects of OIIP toxicity. This approach will 
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provide us with furthe r insight and information regarding the cellular 
mechanism(s) of OHP toxicity. Further, a drug capab le of providing pro-
tection against OHP toxici ty will be of i mmense value in that it will 
permit wid e r and more frequ ent use of OHP in a variety of clinical con-
ditions and may also prevent any tox ic effects occurring during the 
course of undersea and aerospace exp loration. 
We have selected to study the effects of th ree agents. The pro-
t ective e ff ec ts of two of these agents against s ome of the aspects of OHP 
t oxicity a r e we ll doclllnented . These two agents are pargyline (Blenkarn 
et ~l·, 1969 ; Faiman ~al., 1971) and succinic acid ( Sanders~..§.!.., 
1969). Since preliminary investiga~io~s revealed that L-ascorbic acid 
protecred agains t OHP convulsions and since very little previous work 
had been done with this agent in the area of OHP toxicity, we included 
ascorbic acid in our i nvestigation. 
The protective effect of pargyline against OHP convulsions was 
originally thought to be due to the ability of this agent to elevate 
brain amines (NE, 5-HT and DA) si".1ce it had previously been sho'.m that 
OHP exposure decreased brain NE and 5-HT (Faiman and Heble, 1966) . 
Subsequent invest igation revealed that the protective effect of the 
MAO inhibitors was not altered by amine prec ursors or amine synthesis 
inhib itors (Blenkarn ~ al. , 1969; Faiman ~ al. , 19 71) . The conclusion 
reached by both groups of investigators was that th e protective effect 
of MAO inhibitors was unrelated to altered turnover rat e s or absolute 
brain levels of the se amines (Blenkarn et al ., 1969; Faiman et al ., 
1971). 
Various MAO inhibitors have been shown to elevate brain GABA 
levels (Balzer ~ ..§1_., 1960; Popov and Hattheis , 1969) and decreased 
levels of brain GABA have been shown to be involved in the etiology of 
OHP convulsions (Wood, 1970). There have been many reports in recent 
years concerning the role of GABA as an inhibitory transmitter in the 
CNS (Roberts, 1962; Kravitz, 1967). Asids from the fact that GABA's 
role as a CNS transmitter has not yet been clearly elucidated, it has 
been shown to have definite neuronal inhibitory properties in the CNS 
(Roberts, 1962; Kravitz, 1967) and by virtue of this, may be expected 
to play a role in the etiology of convulsive episodes. In brief , the 
main points that support this hypothesis are the facts that OHP de-
creased GABA , the decrease was specific for GABA and occurred prior to 
OHP convulsions and GABA administration prevented OHP convulsions 
(Wood, 1970). 
It is nm.,r well accepted that ammonia is a convulsant agent 
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(i/ o] fe and Elliott, 1962). Further, brQin ar.lillonia hc:s been shown to be 
significantly elevated during OHP exposure (Gershenovich and Krichen-
skoya, 1954; Szam, 1969) and the greatest elevation occurred concur-
rently with the onset of OHP convulsions (Gershenovich and Krichenskoya, 
1954). The MAO inhibitors may prevent the contribution of &-nmonia to 
the ammonia pool by preventing the enhanced catabolism of biogenic 
amines (Faiman and Heble, 1966) or inhibition of the Krebb 's cycle by 
OHP (Dickens , 1962) which may reduce the flow of ammonia acceptors 
resulting in an elevation in brain ammonia . 
This investigation was undertaken to investigate the effects of 
the aforementioned drugs on various aspects of OHP toxicity with respect 
to the possibl e involvement of altered brain GABA and/or &-nmonia metab-
olism in the protective phenomenon. 
The hypotheses to be tested are : 
1 . The protective effect of pargyline , succinic acid and ascorbic 
a cid against OHP toxicity is related t o the ability of these agents 
to prevent the OHP-induced decrease in brain GABA levels . This 
e ffec t on brain GABA is mediated by increased synthesis and / or 
decreased degradation of GABA . 
2. The protective effect of pargyline, succinic acid and ascorbic ac id 
is also related to the ability of these agents to preven t the ORP-
i nduced elevation in brain ammonia and decrease in brain glutamine 
l evels . 
3. I n addition to the protective effect of these agents on OHP convul-
s ions, pargyline, succinic acid and ascorbic acid also protecl-
against OHP-induced pulmonary damage and post- OHP mortality . 
10 
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II. LITERATURE SURVEY 
HYPERBARIC OXYGEN CONVULSIONS 
The most dramatic manifestation of oxygen toxicity at pressures in 
excess of 2 to 3 ATA (33 to 66 ft) is .the onset of convulsions. The 
first r eport concerning the effects of exposure to OHP was that of 
Bert (1878), in which he described in detail the incidence of convul-
sions in various animal species exposed to hyperbaric o:<.ygen . 1his \:ori~ 
was subsequently confinned by nurr,erous other investigators wl~ose work 
has been reviewed by Bean (1945) and Haugaard (19 68). Tr,e seizures take 
t he form of generalized convulsions which are frequently, but not always, 
preceded by minor twitching of the head and forelimbs. 
OHP convulsions have also been reported to occur j_n man (Behnke 
~al., 1934-5). Lambertsen (1965) described the course of progressive 
s ymptoms as follows : 
The convulsions are usually but not always preceded 
by the occurrence of localized muscular t witching , 
especially about the eyes, mouth and forehead. Small 
muscles of the hands may be involved and incoordination 
of diaphragm activity in respiration may occur . These 
phenomena increase in severity over a period which may 
vary from a few minutes to nearly an hour with essentially 
clear consciousness being retained . Eventually an abrupt 
spread of excitation occurs and the rigid tonic pha~e of 
the convulsion begins. The t onic phase lasts for about 
30 secs and is accompanied by an abrupt loss of conscious-
ness. Vigorous clonic contractions of the muscular groups 
of head and neck, trunk and limbs then occur becoming 
progressively less violent over abcut one minute . 
12 
HYPERBARIC OXYGEN-INDUCED PULMONARY DAMAGE 
Smith (1899) carried out the first extensive investigation 
on the effect of increased oxygen tensions on the lungs of animals. He 
showed that oxygen was a lung irritant producing inflamma tion and conges-
tion and that these effects occurred at partial pressures of oxygen less 
than those r equired for the onset of convulsions. At pressures less t han 
0.7 ATA oxyg en , damage occurred very slowly , if at all , and greater than 
3 ATA, there was the overshadowing onset of convulsions . Clark and 
Lambertsen (1971) have recently reviewed pulmonary oxygen tox icity . 
The overt sign of lung damage in OHP-exposed animals was the occur-
rence of dyspnea (Gesell , 1923; Paine~ a~. , 1941). Gross ex~rrina tion 
c f lungs showed pulmonary damage consisting of extensive areas of hemor-
rhage and edema (Karsner , 1916; Karsner and Ash , 1917). Karsner (1916) 
r~porte<l the occurrence of congestion, edema , epithellal deg~neration 
and. desquamation , fibrin fonna tion and pneumonia in rabbi ts exposed to 
80-90 percent oxygen for 24-48 hours. Thickeniug and hyalinization of 
the walls of the pulmonary arteries was observed by Smith et al (1932), 
and the occurrence of atelectasis in the lungs of exposed animals has 
also been clearly established (Behnke~ al ., 1934; Van Den Brenk and 
Jamieson , 1962) . 
POSSIBLE RELATIONSHIP BET~·1EEN HYPERBARIC 
OXYGEN-INDUCED CO \!VULSIONS A1~D PULMONARY DAi.\fAGE 
The studies of Smith (1899) demonstrated that pulmonary pathology 
occurred in the absence of OHP convulsions. Further, pulmonary damage 
occurred during relatively short periods of exposure to OHP (2-3 AtA) 
(Bean and Johnson, 1955), although the onset of s eizures was the most 
dramatic sign of OHP toxicity at these high pressures (Stadie ~ al., 
1944) . The observations of Johnson and Bean (1957) and Wood~ al . 
( 1965) that lung damage occurred in animals tha t had suffered severe 
seizures raised the poss ibility that there may be a cause and effect 
relationship between s e izures and this r apidly developing pulmonary 
damage. 
This possible relationship was discounted by Shilling and Adams 
(1933) when they found that pentobarbital e limina t ed seizures but not 
l ung damage in Q}fP-exposed rats and tha t no lung damage occurred after 
chemically induced (st rychnine ) seizures . J amieson and Van Den Brenk 
(1962), however , fo und pentobarbital to be as effective in reducing 
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lung damage as it was in preventing the onset of seizures. Further, 
s evere lung damage has been reported after seizures induced by thiosemi-
carbazide (Tennekoon, 1954) or pentylenetetrazo l (Riechert, 1941). Bean 
et al. (1966) found tha t anaesthetic agents protected against both 
seizures and lung damage induced by chemical agents 01 Oi:IP whereas 
sympatholytic agents protected against only pulmonary pa thology . These 
investigators suggested that pulmonary damage was largely the result of 
some neuroendocrinogenic component of the seizure . 
It is still not established whether slow or rapid OHP-induced 
pulmonary damage are brought about by the same mechanism, but microscopic 
examinatio~ of both types of lung r evealed little qualitative differenc£ 
between the two types of lung damage (Van Den Brenk and Jamieson, 1962) . 
It may be tha t development of pulmonary damage at less than 2 ATA oxygen 
involves the sympathetic nervous system and tha t onset of seizures at 
higher oxygen pressures stimulates this portion of the nervous system 
thereby hastening the onset of lung damag e. 
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EFFECT OF ALTERATION OF BRAIN AHINES ON SEIZURE SUSCEPTIBILITY 
Schlesinger ~~ al. (196 5) found siguificant differences in brain 
5-HT and NE in mice of certain seizure-susceptible strains (DBA/2J), 
relative to seizure-resistant mice (C57Bl/6J), at the age when seizure 
incidence was maximal (2 1 days). These investigators (S chlesinger et 
al., 1968) also observed that agents that l owered brain amines (reser-
pine , alpha-methyl-p-tyrosine, p-chlorophenylalanine) increased the sus-
ceptibility of mice to audiogenic seizures, while agents which increase 
brain amines (H,.'\O inhibitors, 5-hydroxytryptophan) had a protective 
effect agRinst audiogenic seizures. MAO inhibitors have been reported 
to inhibit various components of audiogenic seizures (Plotinkoff ~ ~~· , 
1963). Lehman (1967) observed that HAO inhibitors tendE.:d to protect 
agains t audiogenic seizures in mice, while reserpine iL1creased their 
severity. 
Reserpine, which releases brain amines, enhanced electroshock con-
vulsions, while MAO inhibitors, which increase brain am ines, protec t ed 
against these convulsions (Prockop, ~ .:il. , 1959). Exposure to OHP 
lowered NE in both mouse (Faiman and Heble, 1966) and rat (Haggendal , 
1967; Haggendal , 1968) brain. Brain 5-HT was decreased in mouse (Faiman 
and Heble, 1966 ) and increased in rat (Haggendal , 1968) . Reserpine 
shortened the time to onset of OHP convulsions in mice (Haggendal , 1968; 
Oliver~ al ., 1970) , while the MAO inhibitors nialamide (Haggendal , 
1968), i proniazid and pargyline increased the latency to OHP seizures 
(Blenkarn ~ ~·, 1969) . 
From the preceding it would appear that brain amines play a role 
in OHP-induced convulsions , but this was not found to be the case after 
subsequent investigation. Inhibitors of NE synthesis (alpha-methyl-p-
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tyrosine) and 5-HT (p-chlorophenylalanine ) lowered brain NE and 5-HT 
content but had no effect on OHP tolerance in rats (Blenkarn ~ al., 
1969) or mice (Faiman ~al., 1971). The amine precursors 5-hydroxy-
tryptophan elevated 5-HT levels and 3,4-dihydroxyphenylalanine elevated 
NE and DA levels without producing any significant effect on OHP 
tolerance in rats (Blenkarn ~ al. , 1969) or mice (Faiman ~ al. , 
1971). Inhibition of dopamine- B-oxidase (EC 1.14.2.1) by disulfuram 
elevated brain DA levels and increased OHP tolerance (Faiman ~ al. , 
1971). Our preliminary investigations , however , demonstrated tha t the 
dop amine- B-oxida~e inhibitor diechyldithiocarbama te did not alter OHP 
tolerance . Further, since disulfuram , upon absorption, has been shown 
to be converted to its corresponding thiol diethyldithiocarb amate 
(Stromme , 1965) and since di.ethyldithiocarbamate did not provide any 
significant protection against OHP convuisions , it appears that the 
protet:tive effect of disulfuram is not due . to i~hibition of dopamine-
B-oxidase or subsequent elevation of brain DA levels. 
Altered turnov~r rates of NE and 5-HT have also been implicated 
in the etiology of the OHP-induced convulsion (Faiman and Heble, 1966; 
Haggendal, 1967, 1968; Neff and Costa, 1967; Diaz~ al., 1965). 
Blenkarn and coworkers (1969), however, concluded from their studies 
that a direct relationship between OHP central nervous system toxicity 
and 5-HT or NE turnover rates did not exist in rats. Since the findings 
of Faiman et al. (1971) in mice concur with those of Blenkarn et al. 
(1969), the same may be said to be true in the case of mice . 
It appears, therefore, that no dire ct correlation exists between 
OHP convulsions and NE or 5-HT levels or turnover rates in rat or mouse 
brain. As will be seen in the following section , this may also be t rue 
in the case o f electroshock and audiogenic seizures . 
GAMMA-AMINOBUTYRIC ACID AND HYPERBARIC OXYGEN 
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Wolfe and Elliott (1962 ) have reviewed the evidence for the role of 
GABA in convulsions induced under a wide variety of conditions . Al though 
the role of GABA in the brain is not totally understood, a variety of 
evidence points toward its neuro~al inhibitory properties (see Roberts , 
1962) . There is considerable evidence for the involvement of GABA in 
the causation of seizures induced by OHP exposure. This evidence can be 
summarized as fellows : 
1. Exposure of animals to OHP decreased brain GABA (Wo od g al., 1963; 
Wood g al. , 196 7). 
2 . The decreased GABA and OHP convulsions were r eversible (Wood and 
Watson, 1963). 
3. The decrease in GABA occurred prior to convulsions (Wood and Watson, 
1963). 
4. Of the amino acids t ested , the decreas e was specific for GABA (Wood 
and Watson, 1963) . 
5. Susceptibility to OHP convulsions correlated well with the rate of 
decline in brain GABA for different species, different pressures of 
oxygen and differen t stages of developmen t (Wood g al. , 196 7; Wood 
et al., 1969 ). 
6. GABA administration protected animals against OHP convulsions (Hood 
et al. , 1963; Wood et al. , 1966; Wood and Watson , 1968; \food, 1970). 
The metabolic pathway of GABA is shov.m in Figure 1. Glutamic acid 
is metabolized to GABA by GAD and GAHA is then converted to succinic 
s emialdehyde by GABA-T . The final step in t he pathway i s the convers ion 
glutamine 
s yn thetase 
glut am ina.se 
GLUTAMINE -~ 
. '>l + 
~ ATP 
~NH1; 
NH4 
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glu tamic acid 
decarboxylase 
Pyr P 
y-AMINOBUTYRIC ACID 
y-aminobutyric acid 
transaminase 
Pyr P 
SUCCINIC ACID 
Figure 1. GAMMA-Ai'v!INOBUTYRIC ACID-GLUTA'HNE PATHWAY IN BRAIN 
of succinic semialdchyde to succinic acid by succinic semialdehyde de-
hydrogenase (EC 1.2.1.16). Both GAD and GABA-Tare Pyr P dependent 
enzymes (see Baxter, 1970). 
The decrease in brain GABA levels during OHP exposure has been 
shown to be due to inhibition of GAD (Wood ~ al., 1967; Myles and Wood, 
1968). OHP had no effect on either GABA-Tor succinic semialdehyde 
dehydrog enase (Wood~ al., 1967; Myles and Wood, 1968). 
Previously, phenelzine (Popov and Mattheis , 1969) and iproniaz id 
(Balzer ~_al., 1960) , two inhibitors of XAO structurally unrelated to 
pa:::-gyline, were repor ted to elevate brain GABA. The elevation in brain 
GABA after phenelzine was due to inhi bition of the GABA degrading enzyme 
GABA-T (Popov and Mattheis, 1969) . These drugs protect against OHP con-
vulsions (Blenkarn ~~·, 1969; unpublished data). Reserpine dec r eased 
bo th brain GABA (Balzer ~ al., 1960) and the latency to OHP convulsions 
(Oliver et al ., 1970). Iproniazid prevented both the decrease in the 
threshold to electroshock seizures and the decrease in brain GABA caused 
by reserpine (Balzer e~ al., 1960). Amino-oxyacetic acid elevated brain 
GABA, protected against audiogenic seizures (S chlesinger~ al., 1968) 
and decreased the incidence of severe OHP convulsions (Wood and Watson, 
1962). 
From the preceding , it appears that maintenance of normal brain 
GABA levels is an important factor in the susceptibility of animals to 
audiogenic, electroshock or OHP seizures and that the protective effects 
of the MAO inhibitors on these three seizure types may be a consequence 
of their ability to maintain normal levels of brain GABA . 
AMMONIA 
The GABA precursor , glutamic acid, is also the precursor to 
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glutamine. Glutamine synthesis (s ee Figure 1) is the brain's ammonia 
detoxica tion mechanism and thus is important in maintaining the intra-
cellular ammonia levels within a certain range (Katunuma ~ al. , 1965) . 
As mentioned in the introduction, ammonia is a convulsant agent 
(see Dickens, 1962). Elevated brain ammonia levels produced by ammonium 
acetat e (Ugarte~~·, 1968) or ammonium chloride (Salvatore and 
" " . Bocchini, 1961) caused convulsions and pulmonary edema (Konig and Konig , 
1949). Ammonia leve ls were increased during OHP exposure (G ershenovich 
and Krichenskoya , 1954; Szam, 1969) and neutralized ammon i um chloride 
tended to decrea::;._~ the l a tency to OHP convulsions (Gottleib and Cymerman , 
1966). Gershenovich and Krichenskoya (195f1) foun d that the OHP-induced 
elevation in brain ammonia occurred concurrently with the onset of con-
vulsions. They also noted a marked decrease in brain glutamine 
(Gershen~vich and Krichenskoya, 1954). 
The bases for increased levels of ammonia during OHP are not known . 
Enhanced catabolism of biogenic amines in the brain (Faiman and Heble, 
1966) may contribute some ammonia to the ammonia pool. Inhibition of the 
citric acid cycle by OHP (s ee Dickens, 1962) may reduce the flow of 
ammonia acceptors resulting in an increase in brain ammonia. Increased 
brain ammonia was repo ::- ted when the citric acid cycle was interrupted by 
fluoroacetate poisoning (Benitez~ al., 1956). Inhibition of the gluta-
min~ forming enzyme , glutamine synthetase (EC 6. 3 .1. 2), by methionine 
sulfoximine has been shown to result in convulsions (Warren and Shenker, 
1964). These investigators and Folbergrova (1964) reported that methio-
nine sulfoximine administration l ed to a marked and sustained decrease 
in cerebral glut amine and a corresponding rise in ammonia levels. This 
may also be the case in the OllP- induc ed increase in brain ammonia since 
it has been shown that OHP inhibits glutamine synthetase (Gershenovich 
~ al., 1963) . 
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In the CNS , the synthesis of glutamine exhibits priority over other 
energy-consuming reactions and the synthesis of glutamic acid proceeds 
in spite of the risk of a depletion of dicarboxylic acids , suggesting 
t hat the brain must prevent intracellular accumulation of ammonia even 
at a high cost (see Weil-Malherbe, 1962). 
Iproni.:::izid has been shown to decreas e the elevated ammonia levels 
in the blood of patients with severe hepatic damage (Pletscher ~ al. , 
1960). Further, isoniazid, a structural analogue of iproniazid possess-
ing no MAO j_nhibitory activity, does not dec;:-ease the elevated ammonia 
levels in the blood of these patients (Pletscher ~ al., 1960) nor does 
it protect against OHP toxicity (Blenkarn ct al . , 1969). 
From the preceding , it appears that theri is a relationship betwee11 
e l evated ammonia levels and OHP convulsions . Possibly, HAO inhibitors 
may alleviate ORP toxicity by preventing this elevation . 
SllCCINIC ACID 
OHP has been shown to decrease the concentration of ATP in rat 
l iver, kidney and brain (Sanders~ al. , 1966) . ATP is considered to be 
t he primary source of chemical energy in brain tissue and is necessary 
f or maintenance of electrical activity and the "sodium pump" (Kramer~ 
al ., 1968) . Consideration of these facts makes it apparent tha t the 
decrease in brain ATP levels during OHP exposure may be important in the 
etiology of OHP convulsions. This decreas e in ATP may account for inhi-
bition of glutamine synthetase (Gershenovich et al. , 1963) referred to 
in the previous section which considered ammonia involvement in OHP tox icity . 
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The rationale for using succinic acid as a protective agent against 
OHP convulsions lies in this agent's ability to provide reducing equiva-
lents for the mitochondrial electron transport chain with subsequent 
production of ATP . Succinic acid prevented the OHP-induced decrease in 
cerebral ATP and decreas ed the incidence of OHP convulsions (Woodhall 
~ al ., 1971) thus supporting the hypothesis that decreased ATP levels 
are involved in the etiology of OHP seizures. 
It is, ho~ever , possible that the decreased brain ATP l evels in 
them~elves are no t responsible for OHP convulsions and that the actual 
cause of the s eizure is a decrease in brain GABA and/or elevation in 
brain ammoni2 l eve ls secondary to the ATP d~crease. 
For example, the previously mentioned OHP-induced decrease in 
brain glutam.ine synthetase activity (Gershenovich et:. -~ · , 1963) may be 
due to decreased ATP levels since this enzyme is ATP depende~t. This 
enzyme inhibition could then r es ult in the previously reported elevation · 
of brain ammonia levels seen durH1g OHP exposure (Gershenovich and 
Krichenskoya, J954; Szam , 1969) . 
Decreased GABA levels during OHP exposure are due to inhibition 
of GAD (Wood ~ al. , 196 7; Myles and Wood , 1968) and GAD is a Pyr P 
requiring enzyme (Bax ter, 1970). Since pyridoxal kinase (EC 2 . 7. 1.35) 
r equires ATP (Baxter , 1970), the inhibition of GAD and consequent decrease 
in brain GABA during OHP exposure could be due to inhibition of conver-
sion of the Pyr P cofactor to its active form by pyridoxal kinase . 
For this reason and since no one , to our knowledge, has investi-
gated the effects of succinic acid on GABA or amm.onia metabolism, we 
studied the effects of succinic acid on OHP toxicity in relation to 
GABA and ammonia metabolism . 
L-ASCORBIC ACID 
In an attempt to reproduce the data of Oliver~ al. (1970) which 
showed that reserpine decreased the latency to OHP convulsions, it was 
found that ascorbic acid markedly decreased the incidence of OHP con-
vulsions. A 20% solution of L-ascorbic acid had been used to dissolve 
the reserpine base and it was found that the vehicle-treated mice were 
protected against OHP seizures. 
It has been shown that OHP exposure markedly decreased adrenal 
gland ascorbic acid content (Gerschman and Fenn , 1954) as did other 
types of stress such as cold or hypoxia (Sayer and Sayer, 1949). It 
has also been demonstrated that ascorbic acid prottcted 2eainst OHP-
induced pulmonary damage but exhibited no protection against OHP convul-
sions (Jamieson and Van Den Brenk, 1964). 
We, therefore , undertook to investigate the effect of ascorh5c 
acid on OHP toxicity in r elation to GABA and ammonia metabolism in the 
brain. 
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III. EXPERIMENTAL 
ANIMALS 
Swiss albino , random-bred male mice, weighing 25-35 g (Charles 
River Breeding Laboratories, Wilmington, Mass .) were used throughout 
this study . They were housed in animal qua~ters maintained at 21-23°C 
with roor.1 lights alternated on a 12 h light-dark cycle. Commercial 
laboratory chow and water were available ad libitum up to one hour 
before each experiment. Animals were used not earlier than one week 
after receipt from supplier via corrunercial shipper . 
.MATERIALS 
Analytical grade chemicals or equivalent were used througho~t the 
study . Pargyline was supplied by Abbott Laboratories , North Chicago , Ill. 
Sodium succinic acid .hexahydrate was obtained from Cal-Biochem (Los 
Angeles, Calif .) and L-ascorbic acid from Fisher Chemical Co. (Fairlawn , 
N. J.). NADP was obta ined from P-L Biochemicals Inc., Milwaukee , Wisc . 
and NADH from Cal-Biochem . GLDH ( ammonia-free) , GABase and glutaminase 
(EC 3.5.1.2) were obtained from Worthington Biochemicals , Freehold , 
N. J. L-glut amic acid-l-C-14 (sp . act. 52 mCi / mM) was obtained from 
Cal-Atomic , Lo s Angeles , Calif. The cyanomethemoglobin assay system 
was ob tained from Hycel Research Products, Houston , Texas . Pyridoxal 
phosphate was obtained from Cal-Biochem . Hyamine (10-X) was obtained 
f rom New England Nuclear , Boston, Mass . All reagents , buffers and dilu-
tions were made with deionized water . 
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HYPERBARIC OXYGEN CHAfIBER 
The hyperbaric chamber (Figure 2) was designed by Van Tassel (1965) 
and constructed with slight modification by the University of Rhode 
Island Instrument Shop. Modifications included stainless steel endplates, 
an inch-thick plexiglass cylinder (t en in I.D.) two feet in length and an 
elliptical door of one-inch-thick aluminum. The chamber contained three 
ft of 1/8 in copper tubing to allow circulation of water for maintenance 
of a cons t an:: temper a ture (25 ± lcC). Soda lime and calcium chloride were 
placed in the bottom of the chamber to absorb carbon dioxide and moisture , 
respectively . 
EXPOSURE TO HYPERBARIC OXYGEN 
Mice contained in individual plexiglass containers (3 x 3 x 3 in) 
with perforated sides and tops to allow free circula tion of c~1arr.ber air , 
were placed in the OHP chamber. The chamber was flushed with 100% 
oxygen (US P) for three min after which the chamber was compressed to 
five atmospheres (60 psig) at the rate of 30 psig/min (two min). De-
compression was achieved in 15 min (three psig/min) . During the studies 
the flow rate was maintained at three liters/min. OHP exposures were 
for a period of 90 min including flush, compression and decompression . 
EXPERIMENTAL DESIGN 
Mice were divided into four groups : control (vehicle-treated) , 
drug (pargyline, L-ascorbic acid or succinic acid-treated), OHP exposed 
plus vehicle-treated and OHP exposed plus drug-treated. 
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PARAMETERS OF HYPERBARIC OXYGEN TOXICITY 
Convulsions: Time to onset of convulsion was measured as time to 
onset of any convulsive movement . Time to onset of a seizure-complex 
was considered as time to onset of convulsions consisting of t oni~ pos-
t ure , loss of righting reflex ( supine posture on side or back) or other 
s eiz ure lasting 20 sec or more . 
Pulmonary damage : After OHP exposure, both lungs were excised , 
weighed, placed in tared containers and dried to a constant weight at 
75°C. Values were reported as lung weights , as percent body weight 
Clung wet w. ei?J_lt x 100) and percent body we1ght water ccntent of lungs 
( lung wet weight - lung dry weight x lOO) . Lung hemoglobin was deter-1 ung wet weight 
mined by the cyanomether.10globin method of Hainline (1958)_. The Hycel 
standard contained 80 mg cyanomethemoglobin/100 ml. A preweighed vial 
o f Hycel cyanomethemog lobin reagent was dissolved in water to make one 
liter of solution. Lungs were excised, weighed and homogenized in 25 
volumes of ice-cold Hycel reagent . Samples were centrifuged at 10 , 000 
rpm (Sorvall refrigerated centrifuge, rotor SS-34) for ten min as were 
Hycel standards . One ml of supernatant was mixed with two ml of reag ent 
and read vs reagent at 540 mµ on a Beckm2n DB-G grating spectrophotometer . 
Values were reported as hemog lobin content (mg) of both mouse lungs . 
Lethality following hyperbaric oxygen exposure : Mortality was 
recorded at 30 min intervals for the first four hours after OHP expo-
sure . Mortality was then periodically recorded for up to 96 h after OHP 
exposure . 
DRUG DOSAGE 
Pargylin~ , succinic acid and L-ascorbic acid were administered 
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intraper itoneally at several doses and time intervals prior to OHP 
exposure . The dose and time tha t afforded maximal protection against 
OHP convulsions was used in the pulmonary toxicity and mechanistic 
studies. All drugs were prepared j ust prior to use . Drug solutions 
were made in saline and 10 ml / kg was administered . Drug solutions ad-
j usted to pH 6.5 with 2N NaOH or 211 HCl were also administered at the 
dos e and time intervals affording maximal protection in order to deter-
miri.e whether or not pH was a factor in the protective effect of any of 
t he t hree drugs . 
HEASURDIDlT OF GA.11'.·IA- Af1INOBUTYRIC ACID 
The assay procedure was that of Graham and Aprison (1966). Hi ce 
were frozen in liquid nitrogen and kept at - 40°C for 20-24 h . The heads 
were then r emoved with an ice-cold hacksaw and cut longitudinally . 
Whole brains were rapidly removed (45 sec), weighed and homogenized in 
20 volumes of ice-cold 75% (v /v) ethanol-. Samp les were t hen cent r i-
fuged at 5,000 rpm at 0°C for 15 min . The supernates were r emoved and 
stored at 4°C while the pellet was resuspended in 20 volwnes of 75% 
e thanol and centrif uged as above . Both supernate fractions were the n 
combined and mixed thoroughly . Two ml samples were added to s amp le 
vials and evaporated to dryness at 60°C in a water bath with constant 
air flow into each vial. Samples were kept at - 40°C for 21~ h at which 
time GABA was measured . The contents of each vial were suspended in 
five ml of water . Two ml of s ample was shaken with an equal volume ·of 
chlorofcrn and centrifuged in a clinical centrifuge ( International 
Equipmen t Co .) at 3500 rpm for 20 min . 
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The substrate solution1 contained 1 . 4 ml pyrophosphate buffer 
(0. 1 M, pH 8 . 4), 0 . 2 ml NADP (0 . 005 Min water) , 0 . 2 ml alpha-ketoglutaric 
acid (O. l Min buffer) , 0 . 2 ml mercaptoethanol (0 . 06 M in buffer ) and 
t en mg GABase enzyme . Incubation mixtures contained 0 . 1 ml brain sample , 
standard or water; 0. 1 ml pyrophosphate buffer and 0. 04 ml substrate 
s olut ion. Tissue blanks were prepared in the same manner except that no 
GABase was added . Incubations were for 45 min at 37°C in a Dubnoff meta-
bolic shaker . After incubation, 0 . 2 ml a l kaline phosphate2 wa s added to 
the tubes and mixed thoroughly . Tubes were heated at 60°C for 15 min, 
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t hen 0.2 ml of NaOH-H202 was added , mixed thoroughly and the tubes were 
heated at 60°C for ten min . One ml of water was added to the tubes which 
were then mixed thoroughly and the f l uorescence was read immed iately in 
an Aminco-Bowman spectrophotofluorometer (excitation 360 mµ, emission 
460 mµ , sensitivity setti~g at 50 and slit ·i6th of 1/64 in). Value s 
were reported as µmoles GABA/g bra in 0Je t weight) . 
MEASUREMENT OF G.l\MMA-Af1INOBUTYRIC ACID 
TRANSANINASE ACTIVITY 
The GABA-T assay procedure was that of Salvador and Albers (1959) . 
Brains were removed rapidly with the aid of other investigators , weighed 
1Prepared by disso l ving 4 . 46 g Na2P207-lOH20 in 80 ml water . 
Norit-A was added and the solution stirred for 15 min after which t he 
s olution was filtered through Celite . The pH was adjusted to 8 . 4 with 
l N HCl and the vohnne adjusted to 100 ml. The buffe r was stored in an 
amber bottle at 4°C and was prepared fresh 24 h prior to each assay . 
2Prepared by dissolving 15 . 2 g Na3P04-12H20 and 2 . 68 g Na2HP04 
i n sufficient water to make 100 ml. Solution was stored in an amber 
bottle at rooffi temper at ure . 
3Prepared fresh just prior to use by adding 0.2 ml 3% H202 to 
t en ml 10 N NaOH . 
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and homogenized in three volumes of ice-cold l.2S% Triton X-laa . Five 
ml of GABA- a- KG 1 mixt ure was added to a. 2 ml of homogenate . One-half 
ml samples of this mixture were added to a.s ml of DAB reagent 2 
(S a l ganicoff and DeRobertis , 196S) and stored on ice for us e as tissue 
blanks . The r emoval of brains, weighing and homogenizat ion procedures 
took no l onger than 4S min for 2a mice. 
The succinic semialdehyde standard was prepared according to 
Prescott and W&elsch (19 46 ). Twenty mg ninhydrin was mixed with 1 . 4 ml 
glutamir: acid folution (a.aa1 g/rril in a.SN acetic acid) after which time 
2.6 ml of a.SN acetic acid was added . Reagent blanks contained four ml 
of a.SN acetic acid and 2a mg ninhydrin. Reagen t blanks and standards 
were placed in boiling water for ten min . After the tubes were cooled 
in ice, the following r eagents were added at five min intervals: a.4 
ml guanidine carbonate (1 4Z in water ), one ml lead acetate (1 2% in water , 
prepared fresh each day) , a.s ml of SN NaaH and a .l ml water . Tub es 
were centrifuged at 3,aaa rpm for ten min in a clinical centrifuge . 
After centrifugation , a.s ml aliquots of reagent blank and standard 
were added to a.S ml of DAB reagent , mixed and stored on ice. 
The GABA- a-KG mixture containing brain homogenate was incubat ed 
in a Dubnoff metabolic shaker under room air at 37° C for 6a min. After 
incubation , a.s ml aliquots were added to a.S ml DAB reagent . 
water . 
to laa 
a.2S M 
1Prepared by dissolving 2.S7S g GABA and 1.46 g a -KG in sa ml 
The pH was brought to 8 . 4 with SN NaOH and the volume adjust.ed 
ml with water . This mixture was prepared fresh daily and was 
in GABA and 0.1 Min a- KG . 
2Prepared by dissolving 2.8 g 3,S-diaminobenzoic acid HCl i n 2S 
ml 1 H potassium phosphate buffer (pH 5 . 9) (1 vol of 1 M K2HP04 plus 
9 vol of 1 M KH2P04) . The pH was brought to S.9 with SN NaOH and ad-
justed to a final volume of sa ml with phosphate buffer . 
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Samples , tissue blanks , reagent blanks and standards were heated 
at 60 °C for 60 min . Nine ml water was added to each tube and tubes were 
centrifuged at 3 , 000 rpm for ten min. Forty µl of supernatant was mixed 
with ten ml water and samples were read in an Aminco-Bowman spectrophoto-
fluor ometer (excitation 405 mµ , emission 505 mµ, sensitivity setting at 
50 and slit width of 1/64 in) . Values were reported as µmoles succinic 
s emialdehyde / g brain / h. 
NEASURFJ•ii.N'T OF GLUTAHIC ACID DECARBOXYLASE ACTIVITY 
The assay procedure was that of Roberts and Simonsen (1963) . The 
C-14-I.-glutaui c: acid substrate solution was made by combining one ml of 
l-C- 14-L-glutamic acid ( 25 microCi), 25 ml of 0.2 N L- glutamic acid 
. adjusted to pH 6. 5 . with KOH , 10 ml of 5 ~~ (v/v) Triton X-100 , 36 ml of 
0. 4 M potassium phosphate buffer 1 ( pH 6.5) and five mg pyridoxal phos-
phate . This solution was adjusted to a final volume of 100 ml with 0 . 2M 
potassium phosphate buffer2 (pH 6 . 5) . The solution was 5 x 10 - 2 M 
in l-C-14 glutamat e (sp . act . 5 µc/mrnole), 2 x 10-4 Min pyridoxal phos-
phate , 0 . 5% in Triton X-100 and 0 . 2 Min phosphate . The final pH was 
6 . 5 and the mixture was stored in 25 ml portions at -40°C until use. 
The procedure for collection of brain s amp les was as described in 
t he GABA-T assay except that brains were homogenized in seven volumes 
of i ce-cold deionized water . One ml of homogenate was added to a 
s cintillation vial that was us ed as an incubation fl a sk and one ml of 
1Prepared by adding 0 . 4 H dibasic potassium phosphate to 0 . 4 M 
monobasic potass ium phosphate until pH 6 . 5 was reached . 
2Prepared by adding 0.2 M dibasic potassium phosphate to 0.2 M 
monobasic potassium phosphate until a pH of 6 . 5 was reached . 
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Hyamine ( 10-X) was added to another vial. The unit 1 was assembled and 
the homogenates were preincubated at 37°C for ten min during which time 
each flask was flushed with 100% nitrogen for two min . The react ion 
was started by the addition of one ml cf substrate solution (warmed to 
37°C) by means of a hypod ermic syringe. The needles were immediately 
r emoved to seal the unit and the samples were incubated at 37°C in a 
Dubnoff metabo lic shaker. 
At the end of exactly 15 min, 0 . 2 cc of 4N sulfuric acid was added 
to stop t he reaction . The units 'were allmv-ed to shake for another 60 
min t o insure conplete absorption of the C-14-02 by Hyamine (10-X). 
The counting vial was detached and ten ml of scintillation solution2 
was added . Radioactivity was counted in a Packard Tri-Carb liquid 
scintillation spectrometer ( 25% gain setting) . Internal standards of 
C-·lLf toluc.ne (New England nuclear ) ~ :ere added to every other sample for 
det ermination of percent efficiency . All samples were counted for t en 
min. Values were reported as µmoles C02/ g brain/h 
(-s ample cpm - blank cpm x 32 
percent efficiency x 110 ). GAD catalyzes the conversion of one 
mole of L-glutamic acid to one mole of co2 and one mole of GABA . 
1The unit consisted of t wo counting vials connected by a glass U 
tube (1/ 4 i n I . D.). The vials and U tube were connected by means of 1/2 
in lengths of high pressure tubing (soft rubber, 1/4 in I. D., 5/8 in O. D.). 
Two needles (23 gauge, 1 in) per unit were ins erted through the tub~ng 
and removed after addition of C-14 substrate . Sulfuric acid was intro-
duced through the tubing by means of a needle and syringe at the end of 
the incubation period. During pre-incubation and after nitrogen flush, 
needles were stoppered with 1/8 in O. D. glass tubing sealed at both ends. 
2Prepared by dissolving l g POPOP (1, 4-bis [ 2-(5-phenyloxazolyl)] 
benzene) and 0.1 g PPO ( 2,5 diphenyloxazole) in sufficient toluene t o 
make one liter. 
32 
MEASUREMENT OF BRAIN AMMONIA 
Brain samples were collected as described in GABA methods except 
that brains were homogenized in three volumes of ice-cold l N perchloric 
acid. Samples were centrifuged at 15,000 r pm for 15 min at 0°C. One ml 
of supernate was adjusted to pH 5 with 2N KOH and samples were again 
centri fuged at 15,000 rpm for 15 min . This supernatant was used for 
de t ermination of ammonia and glutamine . The assay procedure was tha t 
of Buttery and Roswell (1971) . The substrate solution was made by com-
binfog 27 ml glycerol , 0 . 85 ml GLDH (100 mg/5 ml) , 10 mg NADH , 0 . 121 g 
c.-KG (dissolved in a small amount of buffer and adjusted to pH 7.8 with 
l N NaOH). The volwne of this solution was adjusted to 100 ml with pH 
7.8 potassilllil phosphate buffer 1 (0.133 M). 
This mi xt ure contained 8 .3 x 10-3 Ma-KG , 0.1 M phosphate , 0.166 
mg /I'll GLOR , 0. l mg / ml NADH and 0 . 34 g /rd glycerol and was pH 7. 8. 
This solution was pre-incubated at 37°C for 30 min in order to r emove 
endogenous ammonia . A 2.6 ml portion of this pre-incubated mixture was 
add ed to 0. 4 ml of brain extract and incubations were resumed at 37°C 
for a fur t her 45 min . Nonenzymic controls were run as follows : 0.4 ml 
s apiples were incubated at 37°C for 45 min with 2.6 ml of a pre-incubated 
mixture as described but with GLDH replaced by buffer . For each assay 
ser ies enzymic and nonenz ymic reagent blanks were also incubated in 
which 0.4 ml water replaced the ti ssue s ample. All tubes were stoppered 
to prevent absorption of atmospheric ammonia . Af ter the 45 min incuba-
tion period, six ml water was added to each tube, extinctions were 
measured at 340 mµ in a Beckman DB-G spectrophotome ter and the ammonia 
1Prepared by adding 0.133 M monobasic potassium phosphate to 0.133 M 
dibasic: potassiu.rn phosphate until pH of 7. 8 was reached. 
content of each sample was calculated as follows : 
Incubation 
Enzymic , water 
Enzymic, sample 
Nonenz p ic , water 
Nonenzymic , sample 
Extinction, 340 mµ 
A 
B 
c 
D 
Ammonia content of sample = (A - B) - (C - D) x 1 x 3 µmole 6 .22 
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The calculation utilized the molar extinction coefficient of NADH 
(6 . 22 x 10 3 cm2 ) and values were reported as µmoles amrnonia/g brain 
(wet weigh r.) . 
NEASUREMEt~T or B~IN L-GLUTA)UdE 
L-glutamine was measured by the method of Buttery and Roswell 
(1971) . Neasurer:;ents of glutamine utilized portions of the brain ex-
t racts prep ared for t:.1e ammonia assay so that both ammonia and glutamine 
were simulta~eously measured in each brain. 
Samples of brain extract (0.2 ml) were incubated at 37°C for 90 min 
each with 0.4 ml of 0.1 1 citrate-phosphate buffer1 , pH 4.9 , and 0.2 ml 
glutaminase (2 mg/ml buffer). A 0 . 4 ml portion of each incubation was 
t hen added to 2.6 ml of pre-incubated enzymic ammonia assay mixture and 
maintained at 37°C for 45 min, diluted with six ml water and read at 
340 mµ . This same procedure was followe d in a control incubation with 
O. 2 ml water r ep lacing the brain extract. The initial ammonia content 
of each samp le was taken into account by including incubations contain-
i ng 0. 2 ml brain extract or 0.2 ml water in which buffer replaced 
glutaminase . 
1Prepared by adding 0 . 1 M citric acid to 0 . 2 M disodium phosphate 
until a pH of 4 . 9 was reached (Mcllvaine, 1921) . 
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The L-glutamine content of each sample was calculated as follows: 
Initial incubation 
Glutaminase , water 
Glutaminase , sample 
No glutaminase, water 
No glutaminase, sample 
Extinction 340 mµ 
after GLDH reaction 
w 
x 
y 
z 
L-glut amine content of = (W _ X) _ (Y _ Z) x _2_ x 3 µmole 
original 0.2 ml sample 6.22 
Again the calculation utilized the molar extinction coefficient of 
NADH. Value s were reported as µmoles L-glutamine/g brain (wet weight) . 
STATIS1ICAL HETHODS 
The Student "t" test for independent means and chi-square 2 x 2 
contingency analysis (Dixon and Massey , 1969) were used to test for the 
significance of differences between control and experimental groups . 
Correlation coefficients were calculated using .linear regression analysis 
(Dixon and Massey, 1969). Tests were performed on an Olivetti Underwood 
Programme 101 desk computer and the level of significance was determined 
by comparison of "t" and chi-square value s with values from standard 
tables. 
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IV . RESULTS 
PARGYLINE 
Pilot studies were conducted to ascertain which pretreatment time 
and dose of pargyline produced the l argest decrease in the incidence of 
OHF convul.si(-r.s. The resul ts of this preliminary study are founct in 
Table l of the appendix. The optimal effect in decreasing OHP convul-
s ions was provided by the intraperitoneal injection of 100 mg/kg pargy-
line 30 min prior to OHP exposure (appendix Table 1) . The incidence o f 
OHP co~vulsions was significa~tly decreased by this dose of pargyline 
(Figure 3) . Both the latency to convulsion onset and the latency to 
seizure complex were prolonged by prior pargyline treatment (Fjgure 3) . 
Further , the percentage of animals that had convulsed at the end of the 
90 min OHP exposure was 40% and 20% for convulsion onset and seizure 
complex , respectively , in pargyline- treated mice, whereas all vehicle-
t reated mice had convulsed prior to the end of the OHP test period 
(Figure 3) . That this decreased incidence of OHP convulsions was net 
due to the pH of the pargyline solution (pH 3 . 8) is sho1~1 by the fact 
t hat a pargyline solution adjusted to a pH of 6 . 5 was as effective in 
increasing the latency to OHP seizures and decreasing their incidence 
a s was the more acidic pargyline solution (appendix Table 1) . 
Pargyline aJso significantly decreased pos t-OHP mortality (Figure 
4) . After OHP exposure , 90% of the control mice died within four has 
opposed to a ten% mortality in the case of the pargyline-treated mice 
(Figure 4) . 
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Figure 3. EFFECT OF PARGYLIHE ON HYPERBAIUC OXYGEN CONVULSIONS . 
0 - pargyline (100 mg/kg) , O - saline. Open symbols 
denote significant difference from corresponding saline 
value at the 0 . 05 level using chi- square test in groups 
o f 26-30 mice . 
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Figure 4 . EFFECT OF PARCYLINE ON LETHALITY FOLLOWI 1G HYPEREAr..IC 
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OXYGEN EXPOSURE . ()- pargyline (100 mg / kg) , 0 - saline. 
Open symbols denote significant difference from correspond-
ing saline value at the 0.05 level using the chi-square 
test in groups of 26-30 mice . 
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OHP significantly increased lung weight and lung water content 
(Table 1). Pargyline decreased these changes approx imate ly to control 
levels (Table i). There was also significantly l ess pulmonary hemorrhage 
in pargyl ine-treated mice as evidenced by the fact that OHP exposure 
elevated lung hemoglobin content by 98% in vehicle-treated mice as 
opposed to only the 15% increase seen in pargyline-treated mice (Table 
2). 
Bra i n GABA levels were significantly decreased (35 %) after 90 min 
of OHP exposure (Figure 5) . Pai;;gyline significantly elevated brain GABA 
(42%) in room ai~-exposed mice and prevented t he OHP-induced decrease 
in brain GABA levels (Figure 5). Since GABA leve ls Here highest 120 
min after pargyline inj ec tion (Figure 5), this time per i od was used for 
the dose-response curve (Figure 7). Actual means , standard errors, 
levels of significance and percent chau3.es in brain GABA are shor,m in 
Table 2 of the appendix . There was a signif icant correlation between 
brain GABA Jevels and the susceptibility of the indiv idual mice to OHP 
convulsions i n that the vehicl e-treated mice had l ower GABA l evels and 
shorter latencies to s eizures than did the pargyline-treated mice (Figure 
6). The correl a tion coefficients were 0. 71 and 0.80 for l a t ency to con-
vulsion onse t and l atency to s e i zure comp l ex, r espectively (Figure 6). 
There was also a significant correlation (r = 0. 88 , p < 0.0005) between 
the dose of pargyline a~1inisteretl and the elevation in brain GABA l eve ls 
(Figure 7). The i ncrease in GABA was near- its maximllllt at 100 mg / kg 
since increas i ng the dose of pargyline to 200 mg / kg produced only a 
further seven percent elevation in brain GARA (Figure 7). Ac tual means , 
standard errors , l eve l s of significance and percent changes in brain 
GABA are shown in Table 3 of the appenciix . 
Table 1. EFFECT OF PARGYLINE ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS IN LUNG WEIGHT AND 
LUNG WATER CONTENT 
c 
'.l!"eatment 
Saline 
Saline + 
OHP (60 psig) 
Pargyline 
Pargyline + 
OHP 
Time (min) 
120 
120 
90 
120 
120 
90 
Lung as % 
Body Weight 1 (Mean ± S.E,)c 
0 . 46 ± 0 . 014 
0 . 72 ± 0 . 065a 
0 . 47 ± 0.016b 
0.50 ± O.Olla,b 
% Change 
+5 7 
+2 
+9 
% Wa ter Conten~ 
(Mean ± S. E.) 
77 ± 0 . 4 
81 ± 0 . 3a 
76 ± 0 . 3b 
79 ± o.4a ,b 
e % Change 
+5 
- 1 
+3 
aSignificantly different from saline controls at the 0 . 05 level using the Student " t" test. 
bSignificantly different from saline+ OHP at the 0 . 05 level using the Student " t " test. 
cPargyline (100 mg / kg) or saline (10 ml / kg body weight) was injected intraperitoneally . 
dMean of six pairs of lungs . 
ePercent change from saline controls . Plus represents increase and minus, decrease. 
w 
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Table 2. EFFECT OF PARGYLINE ON HYPERBARIC OXYGEN-INDUCED 
ALTERATIONS I N LUNG HEMOGLOBIN CONTENT 
a 
b mg Treatment Time (min) 
Hemoglobin/lung 
(Mean ± S. E.) e % Ch ange 
Saline 120 8 .55 ± a.so 
Saline + 120 16.97 ± 2 . 41 OHP (60 psig)c 90 +98.5 
Pargyline 120 8 . 39 ± 0.40d (100 mg/kg ) -1.8 
Pargyline + 120 9. 85 0 . 2Sc,d OHP 90 ± +15.3 
~ach value represents the mean of five pairs of lungs . 
bSaline or pargyline (10 ml /kg body weight) was injected intraperi-
toneally . Dose is given in parentheses . 
cSignificantly different from saline controls at 0.05 l evel 
(Studenl "t" test). 
dSignificant l y different from saline + OHP at the 0 . 05 level 
(Student "t" test) . · 
ePlus indicates increase and minus , decrease . 
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Figure 5 . ALTERATION OF HOUSE BRAIN GA1·01A-ANINOBUTYRIC ACID BY 
PARGYLINE AND HYPERBARIC OXYGEN . Percent change is 
r epresen ted as mean ± S.E . Open symbols denote values 
sienificantly different from controls at 0 . 05 level 
using Stuclent "t" test . GABA concentration of control 
animals is given in lJmoles/g brain as mean± S . E . ( ) 
repres ents numb e r of mice used . O- pargyline ( 100 
mg/kg), 0 - saline + OHP (60 psig) . !:::. - pargyline + 
OHP . 
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Figure 6. CORRELATION BETHEEN BRAIN GAHMA-AMINOBUTYRIC ACID AND 
SUS CEPTIBILITY TO HYPERBARIC OXYGEN SEIZURES IN PARGYLINE-
TREATED MICE. 0 - OHP , Cl - pa r gyline. The animals not 
convulsing within 90 min were assigned an arbitrary con-
vulsion l atency of 90 min . P value repres ents rejection 
of the hypothesis that the correlation coefficient (r ) 
equals zero . 
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Figure 7. EFFECT OF VARIOUS DOSES OF PAHGYLINE O~ MOUSE BHAIN 
GAMNA-Al!UmBUTYRIC ACID LEVELS. Pargyline was admin-
is tered 120 min prior to sacrifice. Each point repre-
s ents the mean percent increase ± S.E. of duplicate 
s&~ples. Number in parentheses represents nunber of 
animals used . Open symbo]s denote significant differ-
ence from controls at the 0 . 05 level using the Student 
"t" t est . P value represents rejection of the hypothesis 
that the correlation coefficient (r) equals zero . 
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The activity of the GABA degrading enzyme , GABA-T, in mouse brain 
was not altered by OHP exposure (Tables 3, 8 and 13). Pargyline de-
creased GABA-T activity in the brains of mice exposed to room air at 
normal atmospheric pressure and also in those of mice exposed to OHP , 
although the degree of inhibition was less in the pargyline-treated , OHP-
exposed mice (Table 3). The inhibition of GABA- Tin pargy line-treated, 
ro om air-exposed mice was not significantly different from that observed 
in pargyline-treated mice exposed to OHP . 
OHP exposure (90 min ) decreased the activity of the GABA synthesiz-
ing enzyme , G.i\D, by about 20% (Tables 4, 9 and 14), and pargyline treat-
ment did not significantly alter this OHP-induced decrease in enz~oe 
activity (Table 4) . Pargyline treatment had no effect on brain GAD 
act ivity in mice exposed t o room air (Table 4). 
OHP exposure elevated brair; anmi.onia L~veis and decreased hraia 
glutamine levels (Tables 5, 10 and 15) . The maximal elevation in ammonia 
(17 3%) occurred after 30 min of OHP exposure (Table 5) which was the 
t ime at which most saline-treated mice began to demonstrate severe 
convulsive activity (Figur0 3) . The decreased glutamine levels, on the 
other hand, were greatest after 60 min (37 %) and 90 min ( 36% ) of OHP 
exposure (Tables 5, 10 and 15). Pargyline had no effect on brain 
anunonia or glutamine levels in mice exposed to room air (Table 5). 
Pargyl ine treatment significantly lessened the elevation in brain 
ammonia produced by OHP exposure and partially prevented the OHP-induced 
decreas e in brain glutamine (Table 5) . 
There was a significant correlation uetween brain arrnnonia levels 
and the susce~tibility of the individual mice to OHP seizures after par-
gyline treatment (Figure 8). The correlaticn coefficients were -0. 73 and 
Table 3. ALTERATION OF HOUSE BRAIN GA.'-J}1A-AHINOBUTYRIC ACID TRANS-
AHINASE ACTIVITY BY PARGYLINE ND HYPF.RBARIC OXYGEN 
Treatment µmoles7'g brain/h 
D b . a OHP~timea r ug-t ime (Mean ± s . s . )f 
Saline -]20 0 229 ± 9 . 3 
Saline - 60 30 227 ± 3.0 >0 . 05 -3 
Saline -90 60 225 ± 2 .5 >0 . 05 -2 
Saline - 120 90 223 ± 3. 2 >0.05 -1 
Pargyline -30 0 190 ± 6 . 1 <0 . 005 -17 
Pargyline -60 0 154 ± 9.5 <0 . 0005 -33 
PargyJine -120 0 171 ± c: .... _, . '- <0.0005 -25 
Pargyline -60 30 196 ± 4 .5 <0 . 01 -15 
Pargyline - 90 60 186 ± 4.0 <0.00 25 -19 
Pargyline - 120 90 201 ± 4. () <0 . 01 - 13 
~inutes. 
bSaline (10 ml/kg body weight) or pargyl ine (100 mg / kg) was injecte~ 
intraperitoneally . 
c OHP exposure at 60 psig . 
dStudent "t" test. 
eµmoles succinic semial<lehyde . 
f Each value represents mean of five mice . 
gMinus represents decrease . 
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Table 4. ALTERATION IN MOUSE BRAIN GLUTA.1'1IC ACID DECARBOXYLASE 
ACTIVI TY BY PARGYLINE AND HYPERBARIC OXYGEN 
Treatment µmoles C02/g brain/h D b . a OHP<;_time a pd rug-time (Mean ± S.E.)e % Change 
Saline -120 0 16.3 ± 0.92 
Saline -60 30 13. 7 ± o. 70 <0 .05 -16 
Saline -90 60 12 . 9 ± 0.47 <0.005 -21 
Saline -120 90 12 . 8 ± 0.81 <0 .01 -22 
Pargyline -30 0 16 . 0 ± 0.88 >0 .05 -2 
Pargyline -60 0 15.7 ± 0.46 >0 . 05 -4 
Pargyline -120 0 16.0 
-
0. 76 >0.05 -2 
Pargyline -60 30 14 . 1 ± 1.10 >0.05 -13 
Pargyline -90 60 13.2 ± o. 71 <O . Oi25 --19 
Pargyline -120 90 12 . 8 ± 0.85 <0.01 -21 
~inutes . 
f 
bSaline (10 ml / kg body weight) or pargyline (100 mg/kg) was injected 
intraperitoneally . 
c OHP exposure at 60 psig. 
dStud ent "t" test. 
e Each value represents mean of five mice. 
fMinus represents decrease. 
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Table 5. EFFECT OF PARGYLINE ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS 
IN NOUSE BRAIN AHMONIA AND GLUTAMINE 
Treatment % % 
47 
Drug~timea OHP~timea Am . b monia e Change Glut amineb e Change 
Saline - 60 
Saline - 60 
Fargyline - 60 
Pargyline -60 
Saline -90 
Saline -90 
Pargyline -90 
Pargyline -90 
Saline -120 
Saline -120 
Pargyline -120 
Pargyline -120 
~linutes. 
0 
30 
0 
30 
0 
60 
0 
60 
0 
90 
0 
90 
0.318 ± 0.09 
0.868 .± 0.03f 
o.2s9 ± o.o5g 
0 . 472 ± 0.07g 
0.338 ± 0.05 
0.81.0 f ± 0.1 ·4 
0.309 T O.Olfg 
0.320 ± 0.09 
'J. 6 77 ± 0. 06 f 
0.484 ± 0.94g 
b~moles/g brain i S.E. Mean of five mice. 
+173 
-9 
+48 
- 9 
+46 
+112 
+7 
+51 
4.63 ± 0.12 
3. 74 ± 0.4l 
4. 72 ± 0.27g 
" 4.86 ± 0.25"' 
4 . 1L1 ± 0.25 
J: 
2.60 ± 0.321. 
3.81 ± o . 1s8 
3.95 ± 0 . 15g 
L, . 68 ± 0. 20 
f 3.01 ± o.30·-
4.82 ± 0.17g 
-19 
+2 
+s 
-37 
-8 
-5 
-36 
+3 
3.68 ± 0.32f ,g -21 
cSaline (10 ml/kg body weight) or pargyline (100 mg / kg ) was injected 
intraperitoneally . 
d OHP exposure at 60 psig. 
e Percent change compared to saline controls. Plus represents in~rease 
and minus, decrease . 
fSi gnificantly different from saline controls at the 0.05 level (Student 
"t" test). 
gSignifi cantly different from saline+ OHP at the 0.05 l evel (Student 
"t" test) . 
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- OHP , 0 - pargyline . The an i mals not convulsing wi thin 
90 min ~ere assigned an arbitrary convulsion latency of 90 
min. P value repres en ts rejection of t he hypothesis that 
the cor~elation coeffic i ent (r ) equals zero . 
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-0.80 for convulsion onset and seizure complex, respectively (Figure 8). 
The correlation between decreased levels of glutamine and OHP seizure 
susceptibility (r = 0 . 21) was not significant in the case of latency to 
convulsion onset. There was, however , 2 significant correlation ~r = 
0.65, p < 0.01) between decreased glutamine levels and seizure suscepti-
bility in the case of seizure complex (Figure 9). 
SUCCINIC ACID 
Prelimina ry studies showed that the intraperitoneal injection of 
12 mmoles/kg (l. 39 g/kg) succinic acid 60 min prior to OHP exposure 
d_creasecl the incidence of OHP convulsions more than did other doses g1ven 
at other time intervals (appendix Table 4). Both the latency to convuJ-
sion onset and the latency to seizure complex were prolonged by prior 
succinic acid treatment (Figure 10). The perc~ntage of anirr:als that had 
convulsed at t he end of the 90 min OHP exposure was approximately 60% 
and 40% for convulsion onset and seizure complex , respectively, in 
succinic acid-treated mice , whereas all saline-treated mice had convulsed 
prior to the end of the OHP test period (Figure 10). As in the case of 
pargy line , the decreased incidence of OHP seizures after succinic acid 
treatment was not due to the pH of the drug solution (pH 7.9) since a 
succinic acid solution adjusted to pH 6.5 was as effective as the more 
basic solution in decreasing the incidence of OHP seizures (appendix 
Table 4). 
Succinic acid significantly decreased post-OHP mortality (Figure 
11). After OHP exposure, 85% of the saline-treated mice died within 4 h 
as opposed to only 20% in the case of succinic acid-treated mice (Figure 
11). 
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Figure 9 . CORRELATION BETWEEN BRAIN GLUTAHINE AND SUSCEPTIBILITY TO 
HYPERBARIC OXYGEN SEIZURES IN PARGYLINE-TREATED MICE . 
- OHP ( 60 psig), 0- pargyline (100 mg /kg). The animals 
not convclsing within 90 min were assigned an arbitrary con-
vulsion latency of 90 min . P value represents rejection of 
the hypoth~sis that the correlation coefficient (r) equals 
zero. 
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Figure 10. EFFECT OF SUC:CINIC ACID ON HYP ERBARIC OXYGEN CONVULSIONS . 
0- succinic acid (12 mmoles / kg) , 0 - saline . Open sym-
bols denote significant difference from corresponding 
saline value at the 0 . 05 level using chi-square test in 
groups of 18-20 mice. 
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Figure 11. EFFECT OF SUCCINIC ACID ON LETHALITY FOLLOWING HYPERBARIC 
OXYGEN EXPOSURE . ()- succinic acid (12 mmoles / kg ), O -
s aline . Open symbols denote significant difference from 
corresponding saline value a t t he 0.05 l eve l using chi-
square t est in groups of 18-20 mi ce . 
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Table 6. EFFECT OF SUCCINIC ACID ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS IN LUNG 
WEIGHT AND LUNG WATER CONTENT 
Lung as % 
Body Weight d % Water Content 
Treatmentc Time (min) (Mean ± S. E. ) % Change e (Mean± S.E .) d % Change e 
·-
Saline 150 0.52 ± 0.014 --- 74 ± 0.6 
Saline + 150 0.81 ± 0.047a +56 78 ± l.Oa +6 OHP (60 psig) 90 
Succinic acid 150 0.49 ± 0.008b -6 74 ± 0.2b 0 
Succinic acid + 150 0.61 ± 0.047b +17 74 ± 0.7b 0 OHP 90 
aSignificantly different from saline contrc:ls at the 0.05 level using the Student "t" test. 
bSignificantly different from saline + OHP at the 0.05 level using the Student "t" test. 
cSuccinic acid (12 mmoles/kg) or saline (10 ml/kg body weight) was injected intraperitoneally. 
~ean of five pairs of lungs. 
ePercent change from saline controls. Plus indicates increase . 
V1 
w 
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Succinic acid treatment significantly de creased the OHP-induced 
increase in lung weight and lung water content (Table 6) . There was 
also significantly less pulmonary hemorrhage in succinic acid-treated 
mice as evidenced by the fact that OHP exposure elevated lung hemoglobin 
content by 98% as opposed to the 15% increase seen in the succinic acid-
t reated mice (Table 7) . 
Brain GABA levels were significantly decrease::l (35%) at th e end of 
the OHP t est period (Figures 12 and 19). GABA levels we re elevated by 
about 20% 150 r-1in after succinic acid injection (Figure 12). The maxi-
mal elevation i n GABA levels was seen at 90 min after succinic acid 
treatment (Figure 12), and this time period was used in the dose-
response curve (Figure 14). After 30 min of OHP exposure, GABA levels 
were sti.11 elevated by 20% in the s·uccinic acid-treated mice but this 
level decreased to that of saline-·treated; room air-exposed mice at the 
end of 90 min of OHP exposure (Figure 12). Actual means, standard 
errors , levels of significance and percent changes in GABA levels are 
shown in Table 5 of the appendix. There was a significant correlation 
between brain GABA levels and the susceptibility of the individua l mice 
t o OHP convulsions in succinic acid-treated mice (Figure 13) . The cor-
r elation coefficients were 0 . 56 and 0 . 77 for latency to convulsion ons et 
and latency to seizure complex, respectively (Figure 13) . There was 
a lso a significant correlation between the dose of succinic acid admin-
i stered and the degree to which brain GABA was elevated (r = 0 . 86, 
p < 0.0005) (Figure 14). Although the highest dose of succinic acid 
( 24 mmoles/kg ) elevated GABA levels by 60%, one of the five mice die d 
before sacri f ice an0 the remaining four mice appeared sick (Figure 14) . , 
Table 7. EFFECT OF SUCCINIC ACID ON HYPERBARIC OXYGEN-INDUCED 
ALTERATIONS IN LUNG HEMOGLOBIN CONTENT 
Treatment Time (min) 
Saline 150 
Saline + 150 
OHP (60 psig) 90 
Succinic acid 150 (1 2 mmoles/kg) 
Succinic acid + 150 
OHP 90 
mg Hemoglobin /lung 
(Ne an ± S. E.) 
8.55 ± a.so 
16 . 97 ± 2.4lc 
8.17 ± 0.44d 
9.87 ± 0.56 
a 
e % Change 
+98.5 
-4.5 
. +15.4 
aEach value repres ents the mean of five pairs of lungs. 
bSaline or succinic acid (10 ml/kg body weight) was injected 
intraperitoneally . Dose is given in pa r entheses . 
cSignif icantly different from saline controls at the 0.05 level 
(Student "t" test) . 
dSignificantly different from saline+ OHP at the 0 . 05 level 
(Student "t" test). 
ePlus represents increase and minus , decrease . 
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ALTERATION OF MOUSE BRAIN GAMMA-AHINOBUTYRIC AC ID BY 
SUCCINIC ACID AND HYPERBARIC OXYGEN . Percent change is 
r epresented as mean ± S. E . Opea symbols d e no t e values 
s ign i ficantly different from controls at 0.05 level using 
St ud ent "t" test. GABA con centration of control animals 
i s given in µmoles/g brain as mean ± S. E. Shaded area 
denot e s OHP exposure . ( ) represents numb e r of mice used . 
0 - succinic acid ( 12 mmo les/kg), O - saline + OHP ( 60 
psig) , ~ succinic acid + OHP . 
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Fi gure 13 . CORRELATION BETWEEN BRAIN GPJ11-'1A-ANINOBUTYRIC ACID AND 
SUSCEPTIBILITY TO HYPERBARIC 01.'YGEN SEIZURES IN SUCCINIC 
ACID-TREATED MICE . 0 - OHP, 0 - succinic acid. The 
animals not convulsinr; within 90 min were assigned an 
arbitrary convulsion latency of 90 min . P value repre-
sents rejection of the hypothesis that the correlation 
coefficient (r) equals zero . 
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Figure 14. CORRELATION BETWEEN DOSE OF SUCCINIC ACID AND BRAIN GANHA-
AHINOBUTYRIC ACID LEVEL. Succinic acid was administered 
90 min prior to sacrifice. Open symbols deno te signifi.cant 
difference from saline controls at the 0.05 level (Studen t 
"t" test). P value represents rejection of the hypothesis 
that the correlation ccefficient (r) equa ls zero. At the 
highest dose, 1/5 rr.ice died and the remainjng mice appeared 
sick. 
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Actual means, standard errors, levels of signif icance and percent changes 
in GABA levels are shown in Table 6 of the appendix. 
GABA-T activity was significantly increased (15%) 150 min after 
succinic acid trea tment ; however, the GABA-T activity of succinic acid-
treated mice exposed to OHP was not significantly different from that of 
saline-treated , room air-exposed animals (Table 8). 
GAD activity was also increased (45%) 150 min after succinic acid 
treatment (Table 9) . There was no OHP-induced decrease in GAD activity 
in succinic acid-treated mice (Table 9); in fact, GAD activity was sig-
nificantly increased (23%) in succinic acid-treated mice after 30 min 
of OHP exposure. This increase in GAD ac tivity was reduced to about 10% 
after 90 min of OHP exposure (Table 9) . 
The OHP-induced increase in brain anurtonia levels was significantly 
less in succinic acid-treated mice than in saline-treated mice, and 
succinic acid-treated mice did not exhibit significantly greater a~monia 
l evels than did saline-treated , room air-exposed animals (Table 10). 
The OHP-induced decrease in brain glutamine l evels was also significantly 
less in succinic acid-treated mice (Table 10) . Glutamine l evels were 
not significantly decreased in succinic acid-treated, OHP-exposed mice 
when compared to saline-treated, room air-exposed controls (Table 10). 
As in the case of pargyline , there was a significant correlation between 
elevation in brain ammonia levels and the susceptibility of the indivi-
dual mice to OHP seizures in succinic acid-treated mice (Figure 15). 
The correlation coefficients were -0.76 and -0.81 for l atency to con-
vulsion onse t and latency to seizure complex , respectively (Figure 15). 
The correlation between decreased glut amine levels and OHP seizure sus-
ceptibility (r 0.27) was not significant in the case of convulsion 
Table 8. ALTERATION OF HOUSE BRAIN GAMHA-Af1INOBUTYRIC ACID TRA~·TS -
AMINASE ACTIVITY BY SUCCI HC ACID AND HYPERBARIC OXYGEN 
Treatment e brainfh D b . a OHP<:..timea 
µmole s /g 
pd % Changeg rug-time (Mean ± S. E. ) 
Saline -150 0 224 ± 3.6 
Saline -90 30 227 ± 3 . 0 >O. 05 +l 
Saline -120 60 225 ± 2 . 5 >0.05 0 
Saline -150 90 223 ± 3 . 3 > o. 05 0 
Succinic 
-60 0 24 7 ±. 5.3 <O . 01 +10 
acid 
Succinic 
-90 0 262 ± 7. 6 < 0. 005 +17 
acid 
Succinic 
-150 0 258 ± 7 . 6 <0 . 005 +15 
acid 
Succinic 
- 90 30 220 ± 4.4 > o. 05 0 
acid 
Succinic 
-120 60 224 ± 3 . 0 > 0 . 05 0 
acid 
Succinic 
-150 90 223 ± 3 . 3 > o. 05 0 
acid 
C\1inutes . 
bSaline (10 ml/kg body weight) or succinic acid (12 mmoles/kg) was 
injected intraperitoneally . 
c OHP exposure at 60 psig. 
d Studen t "t" test. 
eµmoles succinic semialdehyde . 
f Each value repres en ts mean of five mice . 
8Plus r epresen ts increase . 
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Table 9. ALTERATION OF MOUSE BRAIN GLUT.AJHC ACID DECARBOXYLASE 
ACTIVITY BY SUCCINIC ACID AND HYPERBARIC OXYGEN 
Treatment 
D b . a rug-time 
Saline 
Saline 
Saline 
Saline 
Succinic 
acid 
Succinic 
acid 
Succinic 
acid 
Succinic 
acid 
Succinic 
acid 
Succinic 
acid 
~inules. 
-150 
-90 
-120 
-150 
-60 
-90 
-150 
-90 
-120 
-150 
OHF-timea 
0 
30 
60 
90 
0 
0 
0 
30 
60 
90 
µmoles C02/g brain/h 
(Mean ± S. E. ) e 
15.5 ± 0.56 
13.7 ± 0. 70 
12.9 ± 0.47 
12.8 ± 0.81 
18.2 ± 0.84 
21.2 ± 0.88 
22.5 ± 0.03 
19.1 ± 0.82 
17.0 ± 0.57 
16.9 ± 0.80 
<0 . 05 
<0 .0025 
<0.0125 
<0 .01 
<0.0005 
<0 .0005 
<0 .0025 
<0.05 
>0.05 
f % Change 
-12 
-17 
-18 
+17 
+37 
+45 
+23 
+9 
+9 
bSaline (10 ml/kg body weight) or succinic acid (12 mmoles/kg) ~-1as 
injected intraperitoneally. 
c OHP exposure at 60 psig. 
dStudent "t" test. 
e Each value represents mean of five mice. 
f Plus represents increase and minus, decrease . 
Table 10. EFFECT OF SUCCINIC ACID ON HYPERBARIC OXYGEN-INDUCED 
ALTERATIONS IN HOUSE BRAIN AMMONIA AND GLUTAI1INE 
Treatment % 
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% 
D c . a rug-time orrf-timea Amrn . b onia e Change Glutamineb e Change 
Saline 
Saline 
Succinic 
acid 
Succini.c 
acid 
Saline 
Saline 
Succinic 
acid 
Succinic 
acid 
Saline 
Saline 
Succinic 
acid 
Succinic 
acid 
-90 
-90 
-90 
-90 
-120 
-120 
-120 
-120 
-150 
-150 
-150 
-150 
0 
30 
0 
30 
0 
60 
0 
60 
0 
90 
0 
90 
0.32 ± 0.09 
0.87 ± 0.03£ 
0.31 ± 0.06g 
0.4 4 ± 0 . 07g 
0.34 i: 0.05 
0.81 ± 0.14£ 
0.34 ± 0.03g 
0.50 ± 0.07g 
0.32 ± 0.09 
0.68 ± 0.06£ 
0.40 ± 0.07g 
0.42 ± 0.04g 
'\1inutes. 
b µmoles/g brain ± S.E. Mean of five mice. 
+173 
-3 
+37 
+140 
0 
+48 
+112 
+25 
+31 
4.63 ± 0.12 
3.74 ± 0.43£ 
4.55 ± 0.15 
4 .74 ± 0 . 15g 
4.14 ± 0.25 
± 0.32£ 2.60 
3.88 ± 0.15g 
0-3. 88 ± 0.22° 
4.68 ± 0.20 
3.01 ± 0.17£ 
4.69 ± 0.24g 
3.74 ± 0.24g 
-19 
-2 
+? 
-3 7 
-6 
-6 
-36 
0 
-20 
cSaline (10 ml/ 1.<g body weight) or succinic acid (12 mmoles/kg) was 
inject ed intraperitoneally. 
d OHP exposure was at 60 psig. 
e Percent change compared to saline controls. Plus represents increase 
and minus, decrease . 
£Significantly different from saline controls at the 0.05 level (Student 
"t" tes t) . 
gSignificantly different from saline + OHP at th e O. 05 level (Student 
"t" test). 
CONVULSION ONSET 
1.2 5 ~ 
r~ ·0.070 
1.0 P< 0.0005 
0.75 
,. .. 0.50 z • 
~ 
(!'. • t:J 0.25 
(!) 
' 0 Cf) 
~ SEIZURE COMPLEX 
0 
• -; 1.25 0 
..., 
-
r = -0.8 1 
1.0 P< 0.0005 
<( 
0 0.75. 
0.50 
<:{ 
0. 25 
an 
0 
I I I I 0 30 60 90 
LATENCY (MIN) 
Figure 15 . CORRELATION BETHEEN BRAIN .1UMONIA AND SUSCEPTIBILITY TO 
HYPERBARIC OXYGEN SEIZURES IN SUCCINIC ACID-TREATED MICE . 
o - OHP (60 psig), - succinic acid (12 mmoles/kg, IP). 
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The animals not convulsing within 90 min were assigned an 
arbitr ary convulsion latency of 90 min . P value represents 
rejection of the hypothesis that the correlation coeffi-
cient (r) equals zero . 
64 
onset. There was a significant correlation between glutamine levels and 
seizure susceptibility (r = 0.66, p < 0.005) in the case of the seizure 
complex (Figure 16). 
L-ASCORBIC ACID 
Preliminary studies (appendix Table 7) showed that the intraperi-
toneal injection of 12 mmoles/kg (2.11 g/kg) of L-ascorbic acid 60 min 
prio r to OHP exposure decreased the incidence of OHP convulsions more 
than did other doses given at other time intervals (append ix Tab l e 7). 
1-ascorbic ac id significantly decreased the incidence of OHP convulsions 
and significan tly increased t he latency to OHP seizures when compared 
to saline-treated mice (Figure 17). In the case of convulsion onset 
and seizure complex, approx imately 20% of the ascorbic acid-treated mice 
had convulsed at the end of the OilP test period as opposed to 100% of 
the saline-treated animals (Figure 17). The decreased incidence of 
OHP seizures after ascorbic acid treatmen t was not due to the pH of the 
drug solution (pH 2.5) since an ascorbic acid solution adjusted to pH 
6.5 was as effective as the more acidic solution in decreasing the in-
cidence of OHP convulsions (appendix Table 7). 
Ascorbic acid-treated mice demonstrated sjgnificantly less post-
OHP mortality than did saline-treated mice for up to 12 h after OHP 
exposure (Figure 18). At the end of 72 h, however, post-OHP mortality 
was about 90% in both groups of mice (Figure 18). 
Ascorbic acid treatment significantly decreased the OHP-induced 
increase in lung weight when compared to saline-treated mice (Table 11). 
In spite of as corbic acid treatment , however , lung weights were signifi-
cantly higher than those of saline- trea t ed or ascorbic acid-treated, 
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Figure 16. CORRELATION BETWEEN BRAIN GLUTAHINE AND SUSCEPTIBILITY TO 
HYPERBARIC OXYGEN SEIZURES IN SUCCINIC ACID-TREATED MICE. 
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O - OHP (60 psig) , O - succinic acid (12 nunoles / kg ). The 
animals not convulsing within 90 min were assigned an arbi-
t rary convulsion latency of 90 min . P value represents re-
j ection of the hypothesis t hat t he correla tion coefficient 
(r) equals zero . 
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Figure 17. EFFECT OF L-ASCORBIC ACID . ON HYPERBARIC O},.'YGEN C0_1VULSIONS . 
0- ascorbic acid (12 nunoles / kg) , O - saline . Open symbo l s 
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Figure 18 . EFFECT OF L- ASCORBIC ACID ON LETHALITY FOLLOHING HYPERBARIC 
OXYGEN EXPOSURE . 0- ascorbic ac i d (12 mmoles/kg) , 0 -
saline . Open symbols denote significant difference from 
co rresponding saline value at the 0. 05 l evel using chi-
square test in groups of 18-19 mice . 
Table 11. EFFECT OF L-ASCORBIC ACID ON HYPERBARIC OXYGEN-INDUCED ALTERATIONS IN LUNG 
WEIGHT AND LUNG WATER CONTENT 
Lung as % 
Body Weight d % Water Content 
Treatmentc Time (min) (Mean ± S . E. ) % Change e (Nean ± S. E.) d % Change e 
Saline 150 0.52 ± 0.014 --- 74 ± 0.5 
Saline + 150 0.81 ± 0.047a +56 78 ± 1.0a +6 OHP (60 psig) 90 
Ascorbic acid 150 0.53 ± 0.022b +2 71 ± o.5b -4 
Ascorbic acid + 150 0.67 ± 0.044a,b +29 78 ± 1. 9a +6 OHP 90 
aSignificantly different from saline controls at the 0.05 level using the Student ''t'' test. 
bSignificantly different from saline + OHP at the 0.05 level using the Student ''t'' test. 
CL-ascorbic acid (12 mmoles/kg) or saline (10 ml/kg body weight) was injected intraperitoneally. 
<\iean of five pairs of lungs . 
ePercent change from saline controls. Plus represents increase and minus, decrease. 
°' 00 
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room air-exposed mice (Table 11) . Ascorbic acid treatment had no signi-
ficant effect on th e OHP-induced increase in lung water content (Table 
11). Ascorbic acid-treated mice exhibited less pulmonary hemorrhag e 
after OHP exposure when compared to saline-treated mice (Table 12). 
There was still, however, a 34% increase in lung hemoglobin in the ascor-
bic acid-treated mice (Table 12) as opposed to only a 15% increase in 
lung hemoglobin seen after pargyline (Table 2) or succinic acid treat-
ment (Table 7) . 
Ascorbic acid treatment had no effect on brain GABA levels in 
room air- exposed mice nor did it prevent the OHP-induced decrease in 
brain GABA levels (Figure 19). Actual means, standard errors, levels 
of significance and pc:cent changes in brain GABA levels are shmm in 
Table 8 of the append:.x. Further , th ere was no significant correlation 
between brajn GA3A leve~s and individu:i.: susceptibility of the mice to 
OHP seizures. The correlation coefficients for latency to convulsion 
onset and latency to seizure complex were 0.23 and 0.27 , respectively . 
Ascorbic acid t reatment had no effect on GABA-T activity in OHP-
or room air-exposed mice (Table 13). Also , ascorbic acid treatment had 
no effect on GAD activity in room air-exposed mice nor did it prevent 
the OHP-induced decrease in GAD activity (Tab l e 14). 
The OHP-induced increase in brain ammonia levels was significantly 
less in ascorbic acid-treated mice, and ascorbic acid-treated mice dem-
onstrated no significant increase (35%) in brain ammonia levels when 
compared to saline-treated, room air-exposed animals (Table 15). The 
" OHP-induced de crease in brain glut amine was also significantly less in 
ascorbic acid-treated ~ice (Table 15). There was no significan t decrease 
in brain glutamine in ascorbic aci.d-treated mice after 30 or 60 min of 
Table 12. EFFECT OF L-ASCORBIC ACID ON HYPERBARIC OXYGEN-
INDUCED ALTERATIONS IN LUNG HEMOGLOBIN CONTENT 
Hemoglobin/lung a b mg Treatment Time (min) (Mean ± S. E.) % Changee 
Saline 150 8.55 ± 0.45 
Saline+ 150 16.95 ± 2.4lc OHP (60 psig) 90 +98 .5 
Ascorbic acid 150 8.93 ± 0.25d (1 2 mmoles/kg) +4 . 4 
As corbic acid + 150 11. 49 ± 0.45c OHP 90 +34.4 
aEach value represents mean of five pairs ·of lungs . 
bSaline or ascorbic acid (10 ml/kg body weight ) was injected 
i ntraperitoneally . Dose is given in parentheses . 
cSignificantly different from saline controls at the 0.05 level 
(S tudent "t" t est ). 
dSignific antly different from saline controls at the 0.05 level 
(S tudent "t" t est ). 
ePlus represents increase. 
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Figure 19. ALTERATION OF HOUSE BRAIN GAf:!HA-AHINOBUTYRIC ACID BY 
L-ASCORBIC ACID AND HYPERBARIC OXYGEN . Percent change 
is r epresented as mean ± S. E. Open symbols denote ·values 
s ignificantly different from controls at 0.05 leve l using 
St udent "t" test. GABA concentra tion of control animals 
is given in µm oles/g brain as mean ± S.E. ( ) r epre-
s ents number of mice used . O - ascorbic acid (12 
mmolcs / kg ), 0 - s a lin~ + OHP ( 60 psig), ~ - ascorbic 
acid + OHP . Shaded area represents OHP exposure . 
Table 13. ALTERATION OF MOUSE BRAIN GAMMA- AMINOBUTYRIC ACID 
TRANSAMINASE ACTIVITY BY L-ASCORBIC ACID 
AND HYPERBARIC OXYGEN 
Treatment e brain/h 
D b . a OHP'=-timea 
µmoles/g d % Changeg rug-time (Mean .J.. S. E.) f p 
-
Saline -150 0 224 ± 3.6 
Saline -90 30 227 ± 3.0 >0.05 +l 
Saline -120 60 225 ± 2.5 >0.05 0 
Saline -150 90 223 ± 3.3 >0.05 0 
Ascorbic 
-60 0 226 ± 4.3 >0.05 +l 
acid 
Ascorbic 
-90 0 223 ± 1. 3 >0.05 -1 
acid 
Ascorbic 
-150 0 226 ± 3.7 >0.05 +l 
acid 
Ascorbic 
-90 30 223 3.5 >0.05 -1 
acid :! 
Ascorbic 
-120 60 223 ± 2.8 >0.05 -1 
acid 
Ascorbic 
-150 90 222 ± 3.4 >0.05 -1 
acid 
C\1inutes. 
bSaline (10 ml/kg body weight) or ascorbic acid (12 mmoles / kg) 
was injected intraperitoneally . 
c OHP exposure at 60 psig. 
d Student 11 t II test. 
e µmoles succinic semialdehyde. 
f Each value represents mean of five mice. 
gPlus represents increase and minus, decrease. 
72 
Table 14. ALTERATION OF MOUSE BRAIN GLUTAdIC ACID DECARBOXYLASE 
ACTIVITY BY L-ASCORBIC ACID AND HYPERBARIC OXYGEN 
Treatmen t 
D b . a OHPc . a rug-time -time 
Saline 
Saline 
Saline 
Sal ine 
Ascorbic 
acid 
Ascorbic 
ac i d 
l~.scorbic 
a c id 
Ascorbic 
acid 
Ascorbic 
acid 
Ascorbic 
acid 
8Minutes. 
-120 0 
-90 30 
-120 60 
-150 90 
-60 0 
-90 0 
-150 0 
-90 30 
-120 60 
-150 90 
µmoles C02/g brain/h 
(Mean± S.E.) e 
15. 6 ± 0. 80 
13.7 ± 0.70 
12.9 ± 0.47 
12.8 ± 0. 81 
15.9 ± 0.66 
15.4 ± 0.53 
15.9 ± 0.36 
13. 7 ± 1.10 
12.1 ± 0.91 
12.8 ± 0.87 
>0.05 
<0.01 
<0.025 
>0.05 
>0.05 
>0.05 
>0.05 
<0.0125 
<0.025 
f % Change 
-12 
-18 
-18 
+2 
-1 
+l 
-12 
-23 
-18 
bSaline (10 ml/kg body weight) or L-as corbic ac id (12 mmoles /kg) was 
injected intraperitoneally. 
c OHP exposure at 60 psig. 
dStudent "t" test. 
eEach value represents mean of five mice . 
f Plus represents increase and minus, decrease. 
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Table 15. EFFECT OF L-ASCORBIC ACID ON HYPERBARIC OXYGEN-INDUC ED 
ALTERAT IONS IN MOUSE BRAIN ANHONIA A~m GLUTAHINE 
Treatment 
D c . a 08_a • a rug-time ~-time 
Saline 
Saline 
Ascorbic 
acid 
Asc:orb.:.c 
acid 
Saline 
Saline 
Ascorbic 
acid 
Ascorbic 
a cid 
Sa rine 
Saline 
- 90 
-90 
-90 
-90 
-120 
-1 20 
-120 
-120 
-150 
-150 
Ascorbic _150 
acid 
Ascorbic 
-150 
acid 
0 
30 
0 
30 
0 
60 
0 
60 
0 
90 
0 
90 
Amm . b onia 
0.32 ± 0 . 09 
0. 87 ± 0 . 03f 
0.38 ± 0 . 06g 
0 . 43 ± 0.04g 
0. 34 ± 0 . 05 
% 
Change 
+173 
+18 
+36 
0 . 81 ± 0 . 14f +140 
o . 38 ± o.osg +11 
0 . 47 ± 0.07g +38 
0 . 32 ± 0.09 
0.68 ± 0.06f +112 
0 . 33 ± 0 . 02g +4 
0 . 43 ± O. Olg +34 
~inutes . 
b µmoles/g brain ± S. E. Mean of five mice . 
Glutamineb 
4 . 63 ± 0 . 12 
3 . 74 ± 0 . 43£ 
4 . 72 ± o. 27g 
4 . 86 ± 0.25g 
4 . 14 ± 0.25 
2.60 ± 0 . 32f 
4 . 16 ± 0 . 29g 
4 . 17 ± 0.20g 
4 . 68 ± 0 . 20 
3.01 ± 0.30£ 
4 . 81 ± 0.27g 
3 . 82 ± 0 . 18g 
% 
e Change 
-19 
+2 
+5 
-37 
0 
0 
-36 
+43 
-18 
cSaline (10 ml/kg body we ight) or ascorbic acid (12 mno les/kg) was 
i njected intraperitoneally . 
dOHP expo3ure at 60 psig. 
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e Percent change compared to saline controls . Plus represent s increase 
and minus, decrease . 
fSignific an tly differ ent from saline controls at the QOS leve l 
(Student "t" tes t ) . 
gSignifican t ly different from saline+ OHP at the 0 . 05 level (Student 
" t" test). 
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OHP exposure when compared to saline-treated, room air-exposed animals, 
but there was a significant decrease of 18% after 90 min of OHP exposure 
(Table 15). The re was a significant correlation betw2en brain ammonia 
levels and the susceptibility of the individual mice to OHP seizures in 
ascorbic acid-treated animals (Figure 20). The correlation coefficients 
were -0.76 and -0.86 in the case of latency to convulsion onset and 
latency to seizure complex , respectively (Figure 20) . There was no sig-
nificant correlation between glutamine levels and seizure susceptibility 
(r = 0.35) in the case of latency to convulsion onset. The correlation 
between glutmnine levels and seizure susceptibility (r = 0 . 75, p < 0.001) 
was, however, significant in the case of latency t o seizure complex 
(Figur e 21). 
CONVULSION ONSET 
1.-2 5 • 
'· 0 r = -0.76 
p < 0.0005 
0.15 
D 
z 0.50 • 
<! 
• ~ 
ID 0.25 
C> 
........ 0 (J) 
w SEIZURE CO MPLE X 
-' 0 
:l: 1.2 5 0 
=4 - r~-o. as 
........ 
1.0 
<( 
p <0.0005 
z 0.75 0 
~ 
~ 0.50 
<( 
0.25 
0 
0 30 60 90 
LATENCY (MIN) 
Figure 20. CORRELAT ION BETWEEN BRAIN Afl}10NIA AND SUSCEPTIBILITY TO 
HYPERBARIC OXYG EN SEIZURES IN ASCORBIC ACID-TREATED HICE . 
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O - OHP (60 psig) , 0 - ascorbic acid (12 nunoles / kg, IP) . 
The animals not convulsing within 90 min were assigned an 
arbitrary·convulsion l atency of 90 min . P value repres en ts 
rej ection of the hypothesis that the correlation coefficient 
(r) equals zero . 
• 
-
2 
I 
0 
SEIZURE CO PLEX 
L 
r= 0 .15 
P< 0 . 001 
0 0 
,E CY ( . I ) 
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Figure 21. CORRELATION BETWEEN BRAIN GLUTAMINE PU D SUSCEPTIBILITY TO 
HYPERBARTC OXYGEN SEIZURES IN ASCORBIC ACID-TREATED MICE. 
- OHP (60 psig), O- ascorbic acid (12 mrnoles / kg , IP ). 
The animals not convulsing within 90 min were assigned an 
arbitrary convulsion latency of 90 min . P value r epresents 
r e j ection of the hypothesis that the correlation coefficient 
(r) equals zero . 
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V. DISCUSSION 
HYPERBARIC OXYGEN CONVULSIONS 
That pargyline protected against OHP-induced convulsions (Figure 
3) is in agreement with the findings of previous investigators (Blenkarn 
~ al. , 1969; Faiman .s:!. al., 1971). Further, the pretreatment time and 
dose of pargyline that provided the greatest degree of protection against 
OHP seizures in mice was the same as that employed by Faiman et ~!. · 
(1971). 
The pretreatment time and dose of succinic acid that provided max-
imal protection against OHP-induced convulsions (Figure 10) ~-<as the same 
as that employed by Woodhall ~ al. (1971). Blenkarn ~ al. (1969) re-
ported that succinic acid was a more effective protective agent against 
OHP seizures than was pargyline; however, we did not find this to be 
true . Although equimolar doses of pargyline (0.5 mmoles/kg) and succinic 
acid (12 w.moles / kg) were not used in our study or in that of Blenkarn 
~ ~· (1969), comparison of the doses of agent that were most effective 
in preventing OHP convulsions showed that pargyline (Figure 3) was more 
effective in increasing the latency to convulsion onset than was succinic 
acid (Figure 10). Both agents in the doses used were, however, approx-
i mately as effective in their ability to increase the latency to seizure 
complex . This discrepancy may be due to the fact that we did not use 
fasted animals as did other investigators (Woodhall ~ al., 1971) since 
we were able to demonstrate .significar:t protection against OHP 
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convulsions after succinic acid treatmen t in non-fasted mice (Figure 10). 
DeFeudis and Elliot t (1967) have reported that the injection of large 
voll.llTles of hypertonic solutions of diverse substances will also increase 
tolerance of animals to OHP convulsions and thus, obscure the basic 
actions of the protective agents being tested. Although we concur that 
our succinic acid solution is indeed hypertonic, we do not consider the 
dosage vollllTle injected (10 ml/kg) to be a large quantity for use in mice 
since it is the vo l l.l111e usually employed in studies conducted in most 
laboratories. Further , injection· of hypertonic solutions of NaC l pro-
duced the same degree of brain dehydra tion as did hype rtonic succinic 
acid solutions, but the protective effect of NaCl against OHP seizures 
was inconsistent compared to the protective effect of succinic acid 
(DeFeudis and Elliott, 1967). Thus, we feel that possible artifacts due 
to fasting or injection of large volumes of hyp er tonic solutions are not 
responsible for the protective effects against OHP convulsions in the 
case of any of the three agents that we have tested. 
Our results also showed that L-·ascorbic acid protected against OHP 
convulsions (Figure 17). Jamieson and Van Den Brenk (1964), however, 
reported a slight decrease in the latency to OHP convulsions after ascor-
bic acid treatment . This discrepancy may be due to two factors. First, 
the dose of ascorbic a cid (1.74 g/kg) used by J amieson and Van Den Brenk 
(19 64) was lower than the dose of ascorbic acid used in our studies 
(2.11 g/kg). Second, J amieson and Va n Den Brenk (1964) us ed a 10 min 
pret reatment time as opposed to the 60 min pretreatment time used in 
our studies. Further, our preliminary results (appendix Table 7) showed 
that a 30 min pretreatment time was not as effective in reducing the 
incidence of OHP seizures compared to the 60 min pretreatment time. 
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In a recent paper, Serrill et~· (1971) reported that ascorbic acid 
decreased the latency to OHP convulsions in mice . Again, the dosage 
employed (0.5 g/kg) was lower than that used in our studies. Also, the 
ascorbic acid was given in combination with an equal dose of acetylsali-
cylic acid (Serrill ~ al. , 1971). We feel that t hese differences are 
due to either the low dosage of ascorbic acid employed or to the fact 
that both drugs were given in combination since highe r doses of ascor-
bic acid (Figure 17) or acetylsalicylic acid (Puglia.£!_ al., 1970) 
given individually protected against OHP convulsions . 
Comparison of the protective effects of pargyline, succinic acid 
and ascorbic acid were based on the doses of the agents that were most 
effective in decreasing the incidence of OHP convulsions. That the doses 
of ascorbic acid and succinic acid employed in the study were equimolar 
is coincidental. 
Ascorbic acid increased the latency to convulsion onset (Figure 
17) more than did pargyline (Fig ure 3) or succinic acid (Figure 10) , 
but all three agents were approximately equal in the i r effectiveness 
in increasing the latency to the OHP s eizure complex . 
Since two of the protective agents used in our studies were 
acidic when in solution, we undertook to determine if protection agains t 
OHP convulsions was related to a pH change caused by injection of the 
acidi c solutions into the peritoneal cavity. Our results showed that 
solutions of pargyline (app endix Table 1), succinic acid (appendix 
Table 4), or ascorbic acid (appendix Table 7) adjusted to pH 6.S with 
2N NaOH or 2N HCl did not decrease the effectiveness of thes e drugs as 
protective agents against OHP convulsions. We, therefore , suggest tha t 
the protective effect of thes e agents against OHP convulsions is not due 
to any pH change prod uced by intraperitoneal injection of an acidic 
substance or basic substance. 
Since OHP exposure decreased body temperature and pargyline en-
hanced this decrease (Puglia~ al., 1970), the protective effect of 
pargyline against OHP convulsions may have been due to hypothennia. 
Since our hyperbaric chamber was not equipped to monitor body tempera-
ture, we were not able to measure body temperature in our studies. It 
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is kno-;m, hm,;ever , that phenacetin, like pargyline, enhanced the de-
crea s e in rectal temperature prod'uced by OHP, but phenacet in , unlike 
pargyline, did not protect against OHP convulsions (P uglia~ al., 1970). 
Further evidence against t he protective e£fect of pargyline, succinic 
acid or ascorbic acid as being due to thei r ability to enhance OHP-
induced hypothennia is provided by the finding that acetylsalicylic 
acid, which protected against OHP convulsions , partially prevented the 
OHP-induced hypothermia (Pug lia ~ al., 1970). 
LETHALITY FOLLOHING HYPERBARIC OXYGEN EXPOSURE 
That pargy line increased the number of animals surviving after OHP 
exposure (Figure 4) is in agreement with the results of previous i nvesti-
gators (Blenkarn ~al., 1969). We have not seen any investigations con-
cerning the effect of succinic acid on post-OHP mortality, but our studies 
have shown that succinic acid, like pargyline, increased the number of 
animals surviving after OHP exposure (Figure 11). J amieson and Van Den 
Brenk (1964) r eported that ascorbic acid treatment did not alter sur-
vival times of mice exposed to OHP; however, these animals were left in 
the hyperbaric chamber until death , and hence , the results are not a 
measure of post-OHP mor tality. We have found that ascorbic acid 
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decreased post-OHP mortality for about 12 h, but at the end of 72 h the 
number of ascorbic acid-treated mice surviving OHP exposure was the same 
as that of saline controls (Figure 18). The possible reasons for this 
lack of protection against post-OHP mortality after ascorbic acid treat-
ment will be discuss ed later in relation to the effect of ascorbic acid 
on OHP-induced alterations in brain GABA and ammonia levels. 
HYPERBARI C OXYGEN-INDUCED PULMONARY D.l\MAGE 
To our knowledge, no investigations have been undertaken to study 
the effects of pargyline or succinic acid on OHP-induced pulmonary 
damage. 
Since adrenergic blocking agents decreased OHP-induced pulmonary 
toxicity (Gerschman et al ., 1955; Johnson and Bean , 1957) and since MAO 
inhibitors can reduce peripheral sympathet ic activity via production of 
"false neurotransmitters" (Kopin ~ al., 1965), we had a t first thought 
that pargyline protection against OHP pulmonar y toxicity (Tables 1 and 
2) may have been due to a similar inhibitory effect on peripheral and /o r 
central s ympathe tic activity . The time required for the production of 
"false neurotransmitters" is, however , much longer (Kopin et al., 1965) 
than that required for pargyline to exert its protective effect against 
OHP-induced pulmonary damage (Tables 1 and 2). Further, it has already 
been established that no apparent correlation existed be tween absolute 
levels or turnover rates of brain NE , DA or 5-HT and sus ceptibility to 
OHP convulsions (Blenkarn ~al., 1969; Fa i man ~t al ., 1971), and 
possibly , this is also true in the case of pulmonary damage . As men-
tioned in the literature review , it is not firmly established whether 
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pulmonary damage is of central origin and a result of seizure activity 
or is due to a direct toxic effect of OHP on the lung . 
Both pargyline (Tables 1 and 2) and succinic acid (Tables 6 and 7) 
were equally effective in preventing the OHP-induced increase in lung 
weight, lung water content and lung hemoglobin content. 
The fact that ascorbic acid prevented the OHP-induced increase in 
lung weight (Table 11) is in agreement with previous findings (Jamieson 
and Van Den Brenk , 1964). Comparison of the effec t of ascorbic acid on 
OHP-induced pul r:conary damage (Tahles 11 and 12) to the effects of sue-
cinic acid (Tables 6 and 7) or pargyline (Tables 1 and 2) shows that 
ascorbic acid was not as effective as the other t wo agents in preventing 
the OHP-induced increase in lung weight , lung water content and lung 
hemoglobin content. Possible reasons for this difference will be dis-
cussed later in regard to the ef fect of ascorbic acid on OHP-induced 
alterations in brain GABA and runmonia levels. 
GAHHA- AMINOBUTYRIC ACID, GLUTANIC ACID DECARBOXYLASE 
Al'lD GAHMA-AHINOBUTYRIC ACID TRA1\TSANINASE 
The OHP-induced decrease in brain GABA shown in Figures 5, 12 and 
19 is in agreement with previous findings (Wood et al., 1963; Wood et 
al. , 1966). 
To our knowledge, the elevation in brain GABA levels after pargy-
line treatment (Figure 5) has never been reported before. This effect 
was due to inhibition of GABA degradat ion by GABA-T (Table 3). Pargy-
line had no effect on the GABA synthesizing enzyme, GAD (Table 4). These 
data are in agreement with Popov and Hattheis (1969) who found tha t 
other HAO inhibitors elevated brain GABA by inhibiting GABA-T, and these 
MAO inhibitors in the doses used had no effect on GAD activity. 
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Succinic acid, on the other hand, elevated GABA levels (Figure 12) by 
increasing GABA synthesis (Table 9). Although the activity of both GAD 
(Table 9) and GABA~T (Table 10) were increased by succinic acid treat-
ment , GAD was stimulated to a greater degree than was GABA-T. We estab-
lished a dose-response relationship between the dose of pargyline or 
s uccinic acid administered and the degree of elevation in brain GABA 
(Figures 5 and 12) although by different mechanis ms . The ability of 
pargyline or succinic acid to prevent t he OHP- induced decrease in brain 
GABA (Figures 5 and 12) is responsible , at leas t in part, for the pro-
tective effects of these agents against OHP toxicity. There was also 
a significant correlation between OHP seizure susceptibility and brain 
GABA levels in pargyline- (Fig ure 6) or succinic acid-treated mice (Fig-
ure 13) . Further support for decreased levels of GABA bein g involved 
in OHP toxicity is provided by the findings that GABA administration 
decreased OHP convulsions (Wood ~ al. , 1963) and pulmonary damage (Wood 
~ al., 1965). 
Results obtained using succinic acid may be explained in relat ion 
to ATP availability. Since ATP is decreased during OHP exposure 
(Woodhall et ~· , 1971) and both GAD and GABA-T are Pyr P requiring en-
zymes (Baxter, 1970), OHP may inhibit pyridoxal kinase thus decreasing 
the availability of the Pyr P cofactor. That OHP inhibits GAD prefer-
entially may be explained by the fact tha t the cofactor is only loosely 
bound to GAD whereas Pyr P has a greater affinity to GABA-T (Baxter , 
1970) and, therefo re , decreased Pyr P availability might be expected to 
have a greater effer.t on the activity of GAD tha n on that of GABA-T . 
Succinic acid, by eeans of increasing ATP levels , could increase Pyr P 
availabil ity and consequently, elevate GAD and GABA-T activity. 
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Succinic acid could also maintain normal ATP leve ls during OHP exposure 
and thus, prevent the OHP-induced decrease in GAD activity. 
Pargyline, like other MAO inhibitors (Tapia and Pasantes, 1971), 
may inhibit GABA-T by preventing combination of the Pyr P cofactor with 
the enzyme thus decreasing GABA-T activity. That pargyline preferenti-
ally inhibited GABA-T and was without effect on GAD may be explained in 
light of the fact that GAD and GABA-T have a different subcellular 
localiza tion (Baxter , 1970). For this reason, pargy l i ne I!lay not be 
allowed access to the subcellular compartment containing GAD and cannot , 
therefore , inhic.i t GAD. 
Although our experiments were all i~ vivo studies and may not ac-
curately reflect cellular events, they do enable us to gain some insight 
as to possible biochemical events and enable us to make the preceding 
speculations . Substantiation of . these speculations would require ex t en-
sive research on the in vitro aspects of OHP toxic ity and the effects of 
pargyline , succinic acid and ascorbic acid thereon. 
The ability of pargyline to e levate brain GABA may at first seem 
paradoxical since pargyline is used as an antidepressant , whereas GABA 
has neuronal inhibitory properties. It may be that GABA is not involved 
in mood, and pargyline's effect on GABA is, therefore, not related to 
pargyline 's ability to combat depres sion. Also , our study involved the 
administration of only one dos e of pargyline and is, therefore, short-
term in nature, whereas chronic administration of pargyline is requir ed 
for this drug to exhibit it s antidepres sant effect. 
Other factors are involved in the production of OHP toxicity as 
indicated by the fact that ascorbic acid pro tected against OHP toxicity 
(Figures 17 and 18; Tables 11 and 12) but did not increase GABA levels 
or prevent the OHP-induced decrease in brain GABA levels (Figure 19). 
Further, there was no correlation between GABA leve ls and OHP seizure 
susceptibility in ascorbic acid-treated mice . 
AI1MONIA AND GLUTAMINE 
The elevation in brain ammonia levels during OHP exposure 
(Gershenovich and Krichenskoya, 1954; Sz am , 1969) is though t to be due 
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to inhibition of glutamine synthetase . (Gershenovich ~ al., 1963). Glu-
tamine synthetase catalyzes the combination of glutamic acid and ammonia 
to form glutamine (Fig ure 1) and this reaction is, therefore, a means 
of ammonia detoxication in CNS . This is believed to be the main path-
way for ammonia detoxication in brain (see Weil-Halherbe, 1962) especial-
l y since the C.:IS does not have all the enzymes of the urea cycle as does 
the liver (Katanrn:na ~ al. , 1965). 
The fact that the increase in brain ammonia levels during OHP 
exposure (Tables 5, 10 and 15) was greatest at the time of maximal 
seizure activity (Fig ures 3, 10 and 17) anrl that administration of am-
monium salts produced convulsions (Salvatore and Bocchini, 1961; Ugart e 
~ al, 1968) and pulmonary damage (Ktlnig and Ktlnig, 1%9) indicates that 
el evated brain ammonia levels may be involved in the etiology of OHP 
toxicity . Support for this hypothesis also lies in the ability of par-
gyline (Table 5), succinic acid (Table 10) or ascorbic acid (Table 15) 
to lessen the OHP-induced elevation in brain am!non i a and to protec t 
agains t OHP toxicity . Further, there was a significant correlation be-
tween OHP seizure susceptibility and brain amfl1oni a levels in pargyline-, 
succinic acid- or ascorbic acid-treated mice (Figures 8, 15 and 20). 
The decrease in brain glut amine levels during OHP exposure (Table 5, 10 
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and 15) also correlated wel l with OHP seizure susceptibility in pargy-
line-, succinic acid- or ascorbic acid-treated mice (Figures 9, 16 and 
21). This decrease is t hough t to be due to inhibition of glutamine syn-
thetase (Gershenovich ~al., 1963); hence, the ability of the brain to 
detoxify ammonia was impaired. 
The source of this ammonia could be, in part, due to increased MAO 
activity in the presence o f elevat ed oxygen t ension (Novick , 1966). 
This would incre2se various deamination reactions resulting in the ob-
served elevation in brain anunonia levels and decrease in brain DA , NE 
and 5-HT during OHP exposure (Faiman et al., 1971). Pargyli_ne offset 
this OHP-induced arrunonia. elevation (Table 5) possibly by prevent ing the 
OHP-induced incre r.ts e in HAO activity. 
Succini c acid prevented the OHP-induced decrease in brain ATP 
levels (Woodhall ~ a l. , 1971) and may, therefore, prevent OHP-induced 
inhibition of glutamine synthetase if the enzyme inhibition is due to 
decrea s ed ATP availability. 
Ascorbic acid, like succinic acid, can supply reducing equivalents 
to the mitochondrial r espirato ry chain (Mapson , 1967) and could, there-
fore, als o prevent the OHP-induced decrease in brain ATP levels. Both 
succinic acid a nd ascorbic acid may in this manner allm·1 the brain ' s 
anunonia detoxicat ion pathway to function normally during OHP exposure 
and consequently , prevent the OHP-induced buildup in brain ammon i a and 
decrease in brain glutamine levels. 
RELATIONSHIP BETl-.TEF.N BRAIN AHMONIA 
AND GAfJM!,·-AHINOB1.JTYRIC ACID 
As can be seen in Figure 1, both ammonia and GABA are intima t ely 
related in that they have Lhe common precursor glutamic acid. Although 
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pargyline, succinic acid or ascorbic acid all protected against OHP con-
vulsions, ascorbic acid was not as effective against the tot a l OHP tox-
icity syndrome. This, and the fact that all three agents lessened the 
OHP-induced elevation in brain ammonia, but ascorbic acid, unlike pargy-
line and succinic acid, did not prevent the OHP-induced decrease in 
brain GABA, may point to a relationship between ammonia and GABA in the 
etiology of OHP toxicity . We feel that decreased brain GABA levels and 
increased ammonia levels a r e primarily res pons ible for the OHP toxicity 
syndrome . 
There is another common link between these protective agents in 
that they all have an effect on the mito chondria whose function is i m-
paired early in the course of OHP toxicity (Haugaard , 1968). Mi tochon-
drial dys f unction could, therefore, a c count for the reported decrease 
in brain ATP levels (Woodhall et al., 1971) and consequent inhibition 
of glutamine synthetase (Gershenovich et al.," 1963) and pyridoxa l kinase 
(Baxter, 1970). This i nhibition could, there fore, account for the 
altered brain GABA and ammonia me t abolism observed in our studie s and 
by others (Wood et al. , 1966; Wood et al. , 1969; Gershenovich and 
Krichenskoya, 1954 ; Gershenovich ~al., 1963). 
If increased HAO activity contributes to mitochondrial dysfunction, 
then pargyline could prevent this effect. Also, }~.O is associated with 
the outer leaf of the mitochondrial memb rane (Sotto casa , 1967; Schnaitman 
~ ~·, 196 7) and pargyline could maintain mitochondrial integrity by 
binding to this membrane-associated enzyme possibly stabilizing the 
mitochondria l menib r ane . In either case, stabilization of mitochondrial 
function could be the result, and consequently , normal ATP leve ls could 
be maintained. 
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Normal ATP levels are maintained after succinic acid treatment in 
OHP-exposed animals (Sanders~~·, 1966), and this may also be true 
in the case of ascorbic acid since both agen ts can supply r educing equiv-
alents to the mitochondrial respiratory chain for ATP production. The 
decreased protective effect of ascorbic acid compared to succinic acid 
could be due to the fact that ascorbic acid enters the respiratory chain 
at a later step than does succinic acid (Mapson , 1967) and consequent ly, 
would not provide for as much ATP produc tion as would succinic acid . 
Therefore , although decreased brain GABA and increased arrunonia 
levels may be responsible for the actual OHP toxic syndro~e , the common 
underlying cause of thes e biochemical changes in GABA , ammon ia and glu-
tamine and GABA enzymes could be due to decreased ATP production or 
availability, and pargyline, succinic acid or ascorbic acid could exert 
their protective effect by maintaining normal ATP levels during OHP 
exposure. 
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VI . SUMMARY AND CONCLUSIONS 
1 . Hyperbaric oxygen produced convulsions and post-OHP mortality and 
increased weight, water content and hemoglobin content of the lungs. 
2 . Pargyline, succinic acid or ascorbic acid protected against all of 
the above aspects of OHP toxicity to varying degrees . The doses of 
pargyline and succinic acid that were maximally effective in pro-
tecting against OHP convulsions were approxi mately equal in their 
ability to reduce the severity of the rest of the OHP toxicity syn-
drome . The dose of ascorbic acid providing maximal protection 
against OHP convulsions was as effective as was pargyline or suc-
cinic acid in decreasing OHP convulsions but was less effective in 
r educing the severity of the other aspects of oxygen poisoning. 
3. OHP exposure decreased brain GABA levels and brain GAD activity but 
had no effect on GABA-T activity . Both pargyline and succinic acid 
i ncreased brain GABA levels and prevented the OHP-induced decrease 
in brain GABA. The ability of these agents to elevate brain GABA 
correlated well with the dose of the agent administered. There was 
a lso a correlation between GABA levels and OHP seizure susceptibility 
i n pargyline- or succinic acid-treated mice. 
4 . Pargyline elevated brain GABA and prevented the OHP-induced decrease 
in GABA via inhibition of GABA-T activity in mice exposed to room 
air or OHP . Pargyline had no effect on GAD activity nor did it pre-
vent the OHP-induced decrease in GAD activity. 
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5. Succinic acid increased GABA-T and GAD activity in room air-exposed 
mice . 
6. Succinic acid increased brain GABA levels by increasing the activity 
of GAD . The i ncrease in GABA-T activity after succinic acid was 
l e ss t han t ha t of GAD , and GABA-T activity returned to control l evels 
during OHP exposure while GAD activity remained slightly elevated . 
7. Ascorbic acid had no effect on brain GABA levels nor did it prev-cnt 
the OHP-induced decrease in brain GABA. Ascorbic acid had no effect 
on the GABA enzyw.es nor did it prevent the OHP-induced decreas2 in 
brain GAD aclivity . There was no correlation between GABA levels 
and OHP seizure susceptibility in ascorb ic acid-treated mice . 
8. Hyperbar ic oxygen exposure increased bra in a~monia and decreased 
brain glutamine levels . 
9. Pargyline, succinic acid or ascorbic acid had no effect on brain 
ammonia or glut amine levels in room air-exposed mice . 
10. Pargyline, succinic acid and ascorbic acid markedly reduced the 
OHP-induced increase in brain ammonia levels and also reduced the 
degree to which brain glutamine levels Fere decreased by OHP expo-
sure . 
11. There was a correlation between brain anunonia levels and OHP seizure 
s usceptibility in pargyline- , si:ccinic acid- or ascorbic a.cid-
t reated mice . This was also true for gJ ctmainc leve ls and OHP sei-
zure suscep t ibility . 
12. The effectiveness of pargyline , succinic acid and ascorbic acid as 
protective agent s against OHP toxicity is related to their ability 
t o alter the deleterious effects of OHP exposure on brain ammonia 
and GABA metabolism . 
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Table 1. EFFECT OF Pr-E:TREATHENT TIME AND DOSE OF PARGYLINE ON 
HYPERBARIC OXYGEN CONVULSIONS 
Minutes of OHP Exposure 
Dose a Pretreatment 10 20 30 40 so 60 70 80 90 
(mg/kg) time (min) N % Convulsed 
CONVULSIO~l ONSET 
0 30 30 0 23 37 60 70 93 100 100 100 
so 30 7 0 13 13 43 S7 86 86 86 100 
100 30 26 0 0 0 19 19 23 3.5 3S 39 
200 30 13 0 0 lS lS 23 23 46 60 60 
100 60 7 0 c lS 13 29 43 43 S7 71 
100 120 10 0 0 10 20 20 40 60 70 70 
100 240 7 0 0 13 29 29 S7 71 71 86 
lOOb 30 7 0 0 0 13 13 29 29 29 43 
SEIZURE COMP LEX 
0 30 30 0 0 7 23 Sl 81 100 100 100 
50 30 7 0 0 0 13 29 29 57 71 •11 
100 30 26 0 0 0 4 .4 8 12 12 12 
200 30 13 0 0 0 8 lS 23 38 54 54 
100 60 7 0 0 0 0 13 29 43 57 57 
100 120 10 0 0 0 10 10 20 20 20 40 
100 240 7 0 0 0 13 13 29 29 57 S7 
lOOb 30 7 0 0 0 13 13 13 13 29 29 
• 
aPa rgyline or saline (10 ml/kg body weight) was inj ected intraperi-
toneally. 
bPargyline solution was adjusted to pH 6. S with 2 NaOH . 
• 
Table 2. ALTERATION OF MOUSE BRAIN GAHMA-AHINOBUTYRIC ACID BY 
PARGYLINE AND HYPERBARIC OXYGEN 
Treatment 
103 
D a . b oupc . b rug-time n -time 
µmoles GABA/g brain 
(Mean ± S. E . ) e f % Change 
Saline -120 0 2. 19 ± 0 . 065 
Sn line -60 30 1. 85 ± 0.108 <0.05 -16 
Saline -90 60 1. 43 ± 0 . 124 <0 . 005 -32 
Saline -120 90 1. 43 ± 0 . 142 <0 . 005 -35 
Pargyline -30 0 2.47 ± 0.057 <0.01 +13 
Pargyline -60 0 2.83 ± 0.142 <0 . 005 +30 
Pargyline -120 0 3.12 ± 0.081 <0.001 +42 
Pargyline -60 30 2.33 ± 0 . 064 >0.05 +6 
Pargyline -90 60 2 . 46 ± 0.077 >0 . 05 +13 
Pargyline -120 90 2. 35 ± o. 091 >0.05 +7 
aSaline (10 ml/kg body weight) or pargyline (100 mg /kg) was injected 
intraperitoneally. 
bM . 
. 1nutes. 
c OHP exposure was at 60 psig. 
dSignificantly different from saline controls at the 0.05 level 
(Student "t" test). 
eEach value represents mean of six mice . 
f Plus repres ents increase and minus, decrease . 
Table 3. EFFECT OF VARIOUS DOSES OF PARGYLINE ON HOUSE 
BRAIN GAffHA-AMINOBUTYRIC ACID 
Treatmenta 
Saline 
Pa-::-gyline 
(25 mg/kg) 
Pargyline 
(SO mg/kg) 
Pargyline 
(100 mg/kg) 
Pargyline 
(200 mg/kg) 
µmoles GABA/g brain, 
Mean ± S. E. (N) 
2.08 ± 0.079 (5) 
2.24 ± 0.089 (5) 
2.48 ± 0.094 (5) 
2. 7 6 ± 0. 08 9 ( 6) 
2.91 ± 0.107 (5) 
>0.05 
<0.02 
<0.001 
<0 .001 
d % Change 
+8 
+19 
+33 
+40 
aSaline or pargyline (10 ml/kg body weight) was injected 
in traperitoneally 120 min prior to sacrifice. Dose is 
given in parentheses. 
bValues were obtained from duplicate samples. 
cSignificantly different from saline controls at the 0.05 
level (Student "t" test). 
d Plus represents increase. 
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Table 4. EFFECT OF PRETREAT 1ENT TIME AND DOSE OF SUCCI NI C ACID ON 
HYP ERBARIC OXYGEN CONVULSIONS 
:Minutes of OHP Exposure 
Dose a Pretreatment 10 20 30 40 50 60 70 80 90 
(mmoles/kg) time (min) N % Convulsed 
CONVULSION ONSET 
0 60 20 0 30 40 70 80 90 100 100 100 
6 60 7 0 0 13 13 43 43 57 71 71 
12 60 18 0 6 11 39 44 50 57 57 57 
15 60 7 0 13 13 29 43 43 57 57 57 
12 30 7 0 13 13 13 29 57 71 71 71 
12 120 7 0 0 13 29 29 29 43 57 57 
12 240 7 0 13 29 29 57 57 71 86 86 
12b 60 7 0 0 0 13 29 43 43 43 57 
SEIZURE cmlPLEX 
0 60 20 0 0 0 30 80 90 90 100 100 
6 60 7 0 0 0 13 29 29 43 43 57 
12 60 18 0 0 0 6 11 11 22 33 33 
15 60 7 0 0 0 0 0 13 43 43 43 
12 30 7 0 0 0 13 13 57 71 71 71 
12 120 7 0 0 0 13 13 13 29 29 43 
12 240 7 0 0 0 29 29 43 57 57 71 
12b 60 7 0 0 0 13 13 13 29 29 29 
aSuccinic acid or saline (10 ml/kg body weight) was inj ec ted intraperi-
toneal ly. 
bs · · ·d UCClnlC aci solution was adjust ed to pH 6.5 with 2N HCl. 
Table 5. ALTERATION OF HOUSE BRAI ~ GAflNA-1' . .HINOBUTYRIC ACID BY 
SUCCINIC ACID AND HYPERBARIC OXYGEN 
Treatment 
D a . b OHPc . b rug-tliile -time 
Saline 
Saline 
Saline 
Saline 
Succinic 
acid 
Succinic 
acid 
-150 
- 90 
-120 
-150 
-60 
-90 
Succinic 
-150 
acid 
Succinic 
acid -90 
Succinic 
acid -120 
Succinic _150 
acid 
0 
30 
60 
90 
0 
0 
0 
30 
60 
90 
µmoles GABA/g brain 
(Mean ± S . E. ) e 
1.97 ± 0.037 
1.72 ± 0.072 
1. 48 ± 0. 06 7 
1. 33 ± o. 080 
2 .40 ± 0.097 
2.58 ± 0.128 
2.36 ± 0.061 
2.42 ± 0.158 
2.23 ± 0.068 
1. 91 ± o. 049 
<0 .005 
<0.001 
<0 .001 
<0.005 
<0 .005 
<0 .001 
<0.02 
<0.01 
>0 .05 
f % Change 
-13 
--2 5 
-33 
+22 
+31 
+20 
+23 
+13 
-3 
aSaline (10 ml/kg body weight) or succinic acid (12 mmoles/kg) was 
injected intraperitoneally. 
bM. inutes. 
cOHP exposure was at 60 psig. 
dSignificantly different from saline controls at the 0.05 level 
(Student "t" test). 
eEach value represents mean of six mice. 
fPlus represent s increase and minus, decrease . 
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Table 6. EFFECT OF VARIOUS DOSES OF SUCCINIC ACID ON MOUSE 
BRAIN GAf1MA-A11INOBUTYRIC ACID 
Treatmenta 
µm oles 
mean 
Saline 2.03 
Succinic acid 2 . 12 (3 mmo les/ kg ) 
Succin i c acid 2 . 37 (6 mooles/kg) 
Succinic acid 2. 63 (12 mmoles/kg) 
Succinic acid 3.25 (24 mmoles/kg) 
GABA/g brain, 
± S.E. (N) 
± 0.063 (5) 
± 0.103 (5) 
± 0 .098 (5) 
± 0.135 (5) 
± 0.098 (4)b 
>0 .05 
<0.01 
<0 .005 
<0.0005 
d % Change 
+4 
+17 
+30 
+60 
aSaline or succ1n1c acid (20 ml/~g body weight ) was injected 
intraperitoneally 90 min prior to sacrifice. Dose is gi~en 
in parentheses. 
bone out of five mice was dead prior to sacrifi ce and the .re-
maining fo ur appeared sick . 
cSignificantly different from saline controls at the 0.05 
level (Student "t" test). 
d Plus represents increase . 
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Table 7. EFFECT OF PRETREATilENT TIME AND DOSE OF L-ASCORBIC ACID ON 
HYPERBARIC OXYGEN CONVULSIONS 
Minutes of OHP Exposure 
Dose a Pretreatment 10 20 30 40 so 60 70 80 90 
(mmoles/kg) time (min) N % Convulsed 
CONVULSION ONSET 
0 60 19 0 42 47 53 74 100 100 100 100 
6 60 7 0 13 43 71 71 71 71 71 71 
12 60 18 0 0 0 17 17 28 28 28 28 
15 60 7 0 0 0 13 29 29 29 43 43 
12 30 7 0 43 43 43 57 57 57 57 57 
12 120 7 0 0 0 13 13 29 29 29 43 
12 240 7 0 0 13 13 29 29 43 43 43 
12b 60 7 0 · o 0 13 13 13 13 29 29 
SEIZURE COMPLEX 
0 60 19 0 0 5 26 74 95 100 100 100 
6 60 7 0 0 13 29 29 71 71 71 71 
12 60 18 0 0 0 0 6 6 17 17 17 
15 60 7 0 0 0 0 13 13 13 29 29 
12 30 7 0 0 13 13 29 29 29 43 43 
12 120 7 0 0 0 13 13 13 29 29 29 
12 240 7 0 0 13 13 13 29 29 43 Lf 3 
12b 60 7 0 0 0 0 13 13 13 13 29 
aAscorbic acid or saline (10 ml/kg body weight) was injected intraperi-
toneally. 
bAscorbic acid solution was adjusted to pH 6.5 wi th 2N NaOH . 
Table 8 . ALTERATION OF MOUSE BP-A.IN GAf!NA-AHINOBUTYRIC ACID BY 
ASCORBIC ACID AND HYPERBARIC OXYGEN 
Treatment 
D a . b OHPc . b rug-time -time 
Saline 
Saline 
Saline 
Saline 
Ascorbic 
acid 
Ascorbic 
acid 
Ascorbic 
acid 
Ascorbic 
acid 
Ascorbic 
acid 
Ascorbic 
acid 
-150 0 
-90 30 
-120 60 
-150 90 
-60 0 
-90 0 
-150 0 
-90 30 
-120 60 
-150 90 
µmoles GABA/g brain 
(Mean ± S. E. )e 
1.97 ± 0.037 
1.72 ± 0.072 
1.48 ± 0.067 
1.33 ± 0.080 
2 . 02 ± 0 . 060 
2.03 ± 0.067 
2.01 ± 0 . 094 
1. 78 ± o. 072 
1. 7 5 ± 0 . 185 
1.31 ± 0.099 
<0 . 005 
<0.001 
<0.001 
>0 . 05 
>0.05 
>0.05 
<0.05 
<0.05 
<0.001 
f % Change 
-13 
-25 
- 33 
+3 
+3 
+2 
-10 
-11 
-34 
aSaline (10 ml/kg body weight) or L-ascorbic acid (12 mmoles/kg) was 
injected intraperitoneally . 
bM. nnutes. 
cOHP exposure was at 60 psig . 
dSignificantly different fr om saline controls at the 0 . 05 level (Stu-
dent "t" test) . 
eEach value represents mean of six mice. 
f Plus represents increase and minus, decrease. 
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